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11. Introduction
1.1 Resveratrol
Antioxidant compounds present in dietary items have gained 
interest because of their benefi cial effects on human health. 
Resveratrol (3,40,5-trihydroxy-trans-stilbene, RV), a polyphenolic 
phytoalexin found in the skin of red grapes and a variety of other 
fruits, functions in plants to protect against fungal infections, injury, 
ultraviolet (UV) radiation (Shakibaei et al., 2009). It was fi rst 
isolated from the roots of white hellebore (Veratrum grandifl orum 
O. Loes) in 1940 (Takaoka M.J. 1940), and later, in 1963, from the 
roots of Polygonum cuspidatum, a plant used in traditional Chinese 
and Japanese medicine. Initially characterized as a phytoalexin, 
resveratrol attracted little interest until 1992, when it was proposed 
to explain some of the cardioprotective effects of red wine. A 
variety of studies have reported that resveratrol has antioxidant, 
anti-infl ammatory, cardioprotective, antibacterial, and antiviral 
activities (Bhat et al., 2001; Yu et al., 2012). In addition, resveratrol 
was found to inhibit proliferation and induce apoptosis in several 
human tumor cells (Joe AK et al., 2002; Aggarwal BB et al., 2004).
1.1.1 Antioxidant activity
Resveratrol prevents oxidative stress by attenuating hydrogen 
peroxide-induced cytotoxicity and intracellular accumulation of 
reactive oxygen species (ROS) at a concentration of 1–100 μmol/l 
2(Jang and Surh, 2001; Liu et al., 2003; Chen et al., 2004; Leiro 
et al., 2004; Yu et al., 2009). Recent studies have demonstrated 
that this polyphenol can also reduce aging- and exercise-induced 
oxidative damage and mitochondrial dysfunction (Ryan et al., 2010; 
Jackson et al., 2011; Sun et al., 2011). Its antioxidant activities 
can be  explained because of its action on different mechanisms. 
First, resveratrol has been reported to be a strong inhibitor of 
nicotinamide-adenine dinucleotide phosphate (NADPH)- and 
adenosine 5’-diphosphate (ADP)-Fe+-lipid peroxidation as well as 
UV light-induced lipid peroxidation, and an effi cient scavenger of 
radicals (Miura et al., 2000). Second, it is able to activate the sirtuin 
class of NAD+-dependent histone deacetylases (Chen et al., 2009; 
Yu et al., 2009). Sirtuins regulate many intracellular pathways via 
the activation of transcription factors and enzymes responsive 
to nutrient availability. SIRT1, the major sirtuin activated by 
resveratrol, mediates the benefi cial effects on longevity and health 
(Brooks and Gu, 2009).
1.1.2 Anti-infl ammatory activity
There is considerable evidence demonstrating the anti-infl ammatory 
properties of resveratrol, including inhibition of ROS production 
in neutrophils, monocytes and macrophages (Martinez and 
Moreno, 2000) and release of various cytokines from macrophages 
and lymphocytes (Feng et al., 2002). The important roles of 
cyclooxygenase (COX)-2 in various tumors and infl ammatory 
diseases have been demonstrated (Kong et al., 2002). COX-2 
3is strongly induced in activated monocytes and macrophages. 
Subbaramaiah et al. (1998) indicated that resveratrol suppressed the 
synthesis of PGE2 by inhibiting COX-2 enzyme activity. Recent 
studies demonstrated that resveratrol signifi cantly attenuated COX-
2 expression and inhibited infl ammatory cytokines such as TNF-a, 
IL-6, and IL-8 through a decrease of intracellular Ca2+ levels and 
extracellular-signal-regulated protein kinases (ERK 1/2), as well as 
through inactivation of the transcription factor NF-kB (Csaki et al., 
2009; Kang et al., 2009). In particular, treatment with resveratrol 
not only suppressed NFkB- regulated gene products involved in 
infl ammation but also inhibited apoptosis by up-regulating Bcl-2, 
Bcl-xL, and TNF-α receptor-associated factor 1, and preventing the 
activation of caspase-3 (Csaki et al., 2009). Most agents that activate 
NF-kB also activate another transcription factor AP-1 (Karin et al., 
1997; Pervaiz, 2003). Resveratrol has been shown to inhibit TNF-
induced activation of AP-1 by c-Jun N-terminal protein kinase 
(JNK) and the upstream kinase MEK (mitogen-activated protein 
kinase kinase or MAPKK) activities (Manna et al., 2000).
1.1.3 Inhibition of platelet aggregation
Regular consumption of red wine is often credited as the explanation 
for the ‘French Paradox’ (Renaud S. & Gueguen R. 1998; Renaud 
S. & de Lorgeril M. 1992), a term coined to describe that the French 
enjoy a low risk of cardiovascular disease despite a diet that is high 
in saturated fat (Richard J.L. 1997). Although regular and moderate 
consumption of any alcoholic beverage  seems to be benefi cial to 
4cardiovascular health, epidemiological studies indicate that red 
wine confers signifi cant additional benefi ts (Gronbaek M. et al., 
1995; Bohm M. et al., 2004).
Platelet aggregation is one of the fi rst steps in the formation of a 
blood clot that can occlude a coronary or cerebral artery, resulting 
in myocardial infarction or stroke, respectively. Moreover, 
inappropriate platelet activation is another major contributor in the 
process of atherosclerosis. Platelets adhesion has also been linked to 
the synthesis of eicosanoids from arachidonic acid (AA) (Fre´mont, 
2000). Crescente et al. (2009) found that resveratrol inhibited AA-
induced platelet aggregation. The mechanisms underlying this 
effect may be associated with the inhibition of PKC activation and 
protein tyrosine phosphorylation.
1.1.4 Effects on neurological conditions
Experimental and epidemiological studies gave evidences that 
resveratrol can exert protective activity against a number of 
neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s 
diseases, multiple sclerosis, amyotrophic lateral sclerosis). This 
polyphenol could exert benefi cial effects on cells not only through 
its antioxidant potential but also through the modulation of 
the synthesis/ degradation of the amyloid  peptide. It has been 
demonstrated that moderate consumption of wine is associated 
with a lower incidence of Alzheimer’s disease (AD) (Wang et al., 
2006). Marambaud et al. (2005) showed that resveratrol (20–40 
μM) could markedly reduce the levels of secreted and intracellular 
5amyloid- peptides by promoting their proteosomal degradation. 
Resveratrol may also be useful in dopaminergic neurodegenerative 
disorders such as Parkinson’s disease (PD) by repressing the 
excitatory neurotransmitter toxicity associated with glutamate. In 
this respect, experimental data have shown that pretreatment of 
SH-SY5Y human neuroblastoma cells with resveratrol resulted in 
an inhibition of dopamine cytotoxicity (Lee et al., 2007).
1.1.5 Anticancer activity
In various types of cancers resveratrol has been reported to inhibit 
all three phases of tumor development: initiation, promotion, 
and progression (Table I). The induction of apoptosis is a key 
mechanism for most anti-tumor therapies. Resveratrol exerts strong 
anti-proliferative activity in many cultured cancer cell lines by 
arresting cell cycle progression and by inducing apoptosis (Bai et 
al., 2010; Gatouillat et al., 2010; Jiang et al., 2010; Kweon et al., 
2010; Vanamala et al., 2010; Wang et al., 2010). The pro-apoptotic 
protein nuclear factor p53 plays a key role in protecting a cell from 
tumorigenesis, blocking the cell cycle or initiating apoptosis if the 
cell is damaged. Resveratrol initiates p53-dependent apoptosis in 
human cancer cells, including prostate cancer, colon cancer, and 
melanoma (Gatouillat et al., 2010; Kai et al., 2010; Vanamala et al., 
2010). Resveratrol also inhibits cell proliferation and contributes to 
the apoptotic cell death by suppressing the expression of cyclin D1 
that causes a G1/S arrest in the cell cycle progression (Bai et al., 
2010; Gatouillat et al., 2010; Wang et al., 2010).
6Table 1. 
Effects of resveratrol on Various Human Cancers in 2010. (Wei Yu et al., 2012)
1.1.6 Antimicrobial activity
Plant polyphenols have been known to possess potential 
antibacterial, antifungal and antiviral activities. Rodriguez-Vaquero 
et al. (2007) have shown that grape wine inhibited microbial growth, 
especially of Escherichia coli, in concentration-dependent manner. 
Moreover, alcohol-free extracts of red and white wine exhibited 
antimicrobial activity to some pathogens such as Staphylococcus 
aureus, Escherichia coli and Candida albicans (Papadopoulou 
C. et al.; 2005). Other studies reported that phenolic compounds 
inhibited some food-borne species such as Salmonella typhimurium 
(Sivarooban T. et al., 2008) and Listeria monocytogenes (Luther M. 
et al., 2007). 
On the other side, the antiviral activity of resveratrol has also been 
reported for several members of the Herpesviridae family (Docherty 
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7et al., 2005, 2006; Evers et al., 2004; Faith et al., 2006; Yiu et al., 
2010), HIV (Zhang et al., 2009), infl uenza A virus (Palamara et al., 
2005) and polyomavirus (Berardi et al., 2009).
1.2 Molecular targets of resveratrol
The mechanisms by which resveratrol exerts its benefi cial effects 
across species and disease models is not yet clear. Experiments in 
vitro have shown promising effects, and have led to the identifi cation 
of multiple targets for this compound.
1.2.1 Effects on cell cycle regulators
The anti-proliferative and pro-apoptotic effects of resveratrol 
have been extensively studied in vitro and confi rmed in several 
in vivo models of neoplastic growth. Resveratrol, at micromolar 
concentrations, has been shown to modulate the major cell cycle 
regulators and arrest cancer cells proliferation at the G1/S phase of 
the cell cycle. The anti-proliferative activity of resveratrol involves 
the induction of p21WAF1 and p27KIP1 and downregulation of 
cyclins D1/D2/E, Cdks 2/4/6, and hyperphosphorylated pRb. In 
other cell types, resveratrol has been reported to arrest the cell cycle 
at the S-phase  as well as at the G2/M-phase, by inhibiting Cdk7 
and p34Cdc2 kinases (reviewed in Athar M et al 2009). Resveratrol 
upregulates the p53 tumor suppressor protein, stimulates its post-
translational modifi cation (Zhang S et al., 2004), induces the 
expression of p53-responsive genes (p21WAF1, p300/CBP, APAF1, 
8and Bak) and causes Bcl2 down-regulation (Narayanan BA et al., 
2003). In addition, p53-independent induction of p21WAF1 and 
subsequent cell cycle arrest in cells lacking wild-type p53 protein 
has been documented. Taken together, the anti-proliferative activity 
of resveratrol involves the differential regulation of multiple cell 
cycle targets depending on both concentration and cell type.
1.2.2 Effects on apoptosis-related proteins
Apoptotic cell death depends on the modulation of genes related to 
apoptotic and survival pathway. Caspase activation is regulated by 
the inhibitor of apoptosis proteins (IAPs) and survivin. IAPs bind 
to caspases and antagonize their activity. p53 induces a number 
of mitochondria-related apoptotic genes, such as Bax, Noxa, 
PUMA, and BID, and represses the anti-apoptotic Bcl2 and cIAPs. 
Resveratrol, through p53 activation, induces the expression of these 
pro-apoptotic proteins, and inhibits the expression of anti-apoptotic 
Bcl2, Bcl-XL, and Mcl-1, directly affecting the mitochondrial 
death pathway. Furthermore, resveratrol was shown to potentiate 
the apoptotic effects of bortezomib and thalidomide through the 
suppression of NF-κB and STAT3 in human multiple myeloma 
cells. In particular, it was observed the down-regulation of anti-
apoptotic genes included cyclin D1, cIAP-2, XIAP, survivin, Bcl-
2, Bcl-xL, Bfl -1/A1, TRAF2 and up-regulation of  Bax/caspase-3-
associated apoptosis (Bhardwaj A et al., 2007).
91.2.3 Inhibition of PI3K/AKT and MAPK pathway
Resveratrol has also been reported to interfere with the 
phosphatidylinositol- 3 kinase (PI3K)/ AKT and mitogen activated 
protein kinase (MAPK) pathway, two key survival cascades. 
Resveratrol derivatives were found to inhibit cell transformation 
by blocking EGF-induced activation of PI3K/AKT in mouse JB6 
epidermal cells (Kolesnick R., 2002). Moreover, the ability of the 
polyphenol to control tumor growth by inhibiting MAPK signaling 
pathway was demonstrated in cervical carcinoma cells exposed to 
UV irradiation (Scarlatti F et al., 2003). However, the antitumor 
activity of resveratrol has also been shown to require MAPK-induced 
p53 activation for subsequent induction of apoptosis (Trincheri NF 
et al., 2007; Chambers AF et al., 1997). In particular, extracellular 
signal-regulated kinase(ERK), c-Jun N-terminal kinase (JNK) and 
p38 kinase were found to mediate resveratrol-induced activation 
of p53 in JB6 mouse epidermal cells. The functional impact of 
resveratrol on MAPK signaling may seems to depend, at least 
in part, on the concentrations of the polyphenol used in different 
settings. In this respect, low concentrations of resveratrol (from 1 
pM to 10 μM) were reported to induce phosphorylation of ERK1/2 
in human neuroblastoma cells, whereas higher concentrations 
(50–100 μM) negatively interfered with phosphorylation of MAP 
kinases (Bernhard EJ et al., 1994).
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1.2.4 Modulation of Transcription Factor
NF-κB
The transcription factor nuclear factor-kappa B (NF-κB) is 
implicated in a number of cellular processes, including immune 
and stress responses, infl ammation, apoptosis, and regulation of 
cell growth. Deregulated NF-κB activity has been implicated in 
various stages of tumorigenesis and linked to a variety of cancers. 
NF-κB is composed of homo- and heterodimeric complexes, 
consisting of linked to a variety p50, p65/RelA, c-Rel, p52, and 
RelB. In its inactive state, NF- κB is sequestered in the cytoplasm, 
via non-covalent interactions with the family of inhibitor proteins, 
IκBs. External stimuli such as mitogens, cytokines, UV, ionizing 
radiation, and bacterial toxins, cause the IkB kinase (IKK) 
mediated-phosphorylation of IkBα and its subsequent degradation. 
Dissociation of IκBα from NF-κB allows nuclear translocation 
of the activated free NF-κB dimer, where it binds to the specifi c 
sequence in the promoter of target genes and induces their 
expression. Resveratrol can suppress IKK phosphorylation and can 
block the degradation of IκBα, thereby inhibiting the activation 
of NF-κB in TPA-stimulated mouse skin (Kundu JK et al., 2006). 
Resveratrol also blocked NF-kB activation induced by PMA, 
LPS, H2O2, okadaic acid, and ceramide (Manna et al., 2000). In 
addition, the polyphenol may down-regulate the expression of NF-
κB-regulated genes, including interleukin-6, Bcl-2, Bcl-xL, XIAP, 
c-IAP, vascular endothelial growth factor (VEGF), and matrix 
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metalloproteinase-9 (MMP-9) (Sun C et al., 2006).
AP-1
The transcription factor AP-1 is composed by a number of different 
dimeric combinations of the Jun (c-Jun, JunB and JunD) and Fos 
(c-Fos, FosB, Fra-1 and Fra-2) families and Jun dimerization 
partners (JDP1 and JDP2) and activating transcription factor (ATF2, 
LRF1/ATF3 and B-ATF) subfamilies. AP-1 plays important roles 
in the proliferation of tumor cells, and induces COX-2, urokinase-
type plasminogen activator, Fos, MMP-9, cyclin D1, and VEGF 
(Lee KW, Lee HJ 2006). Down-regulation of c-Jun and suppressed 
AP-1 activity by resveratrol involve the inhibition of mitogen-
activated protein kinase (MEK)1 /extracellular signal-regulated 
kinase ERK1/2 signaling (Kim AL et al., 2006).
Figure 1. 
Mechanisms of action of resveratrol. (Shankar S et al., 2007)
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1.3 Resveratrol and viruses
1.3.1 Antiviral activity of resveratrol against members of the 
Herpesviridae family
The effects of resveratrol on the Herpesviridae family , in particular 
on HSV-1 (herpes simplex virus 1) and HSV- 2, are among the most 
widely studied. The fi rst report, published in 1999, showed that 
addition of resveratrol in the fi rst 6 h of HSV-1 infection blocked 
viral replication (Docherty J.J. et al., 1999). This inhibition didn’t 
affect either the virus capsid directly or its attachment to the plasma 
membrane, since pre-incubation of the virus or the cells with the drug 
had no effect on viral replication, suggesting that resveratrol acted 
after entry of the virus into the cell. Additional studies demonstrated 
the protective effect of resveratrol in vivo against HSV-1 and HSV-
2 infection by using a hairlessmouse model of cutaneous HSV 
infection and a mouse model of intravaginal infection (Docherty 
J.J. et al., 2005, 2004). Other members of the Herpesviridae family 
have been shown to be susceptible to resveratrol treatment. The 
replication of VZV (Varicella Zoster virus) and HCMV (human 
cytomegalovirus), was inhibited by resveratrol in a dose-dependent 
manner (Docherty, J.J. et al., 2006; Evers, D.L. et al., 2004). As 
observed for HSV-1, resveratrol affected the immediate-early phase 
of VZV replication by blocking the expression of essential viral 
proteins and it reduced early and late gene expression of HCMV. 
However, in contrast with what described for HSV, resveratrol 
could inhibit the early phases of the HCMV entry in the cell and the 
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early cellular signal transduction pathways.
Another member of the family, EBV (Epstein–Barr virus), has been 
shown to be affected by resveratrol. In an in vitro assay, treatment 
of a Burkitt’s lymphoma cell line with the polyphenol largely 
inhibited EBV early antigen induction (Kapadia, G.J et al., 2002). 
Finally, Dyson O.F. et al. (2012) demonstrated that resveratrol, by 
lowering ERK1/2 activity and Egr-1 expression in KSHV-infected 
cells, suppressed viral reactivation from latency.
1.3.2 Activity of resveratrol on retroviruses
Several reports have analyzed the effects of resveratrol on HIV-1 
infection. They propose a possible therapeutic effect of resveratrol 
on HIV infection, suggesting a different mechanisms of action for 
the compound. The ability of the drug to induce the lytic cycle 
of HIV-1 was evaluated by Krishnan and Zeichner (2004). This 
approach consists in combining a drug such as resveratrol, capable 
of inducing the lytic cycle of the virus from the latently infected 
cells, with an antiviral drug in order to eliminate the viral reservoirs 
in the organism. For this purpose, they treated latently HIV-infected 
ACH-2 cells with resveratrol and assessed the production of the 
viral lytic antigen p24. Resveratrol was shown to induce an increase 
of approx. 4-fold in the levels of p24. This effect was attributed 
to the activation of EGR-1 (early growth response gene product 
1), a protein involved in cell-cycle regulation and differentiation. 
Another approach by Heredia and co-workers consists in evaluating 
the synergistic effect of resveratrol on the inhibition of HIV-1 
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replication when administrated together with known inhibitors of 
the viral cycle (Heredia, A. et al., 2000; Wang, L.X. et al., 2004). In 
this case, resveratrol , arresting the cell cycle in S-phase would allow 
a longer exposure of the virus to nucleoside analogue inhibitors. 
Resveratrol alone had only a marginal effect on inhibition of 
viral replication on activated infected-PBMCs (peripheral blood 
mononuclear cells). However, the drug strongly increased the 
antiviral activity of various nucleoside analogues. Although the 
activity of resveratrol on the replication of other retroviruses has 
not yet been reported, resveratrol treatment inhibits the growth 
of HTLV-1 (human T-cell lymphotrophic virus-1) infected cell 
lines (Hayashibara, T. et al., 2002), suggesting a possible antiviral 
activity of the chemical compound also on HTLV-1. 
1.3.3 Antiviral activity of resveratrol on other viruses
Another virus whose replication was shown to be severely 
inhibited by resveratrol is the murine polyomavirus. Resveratrol 
inhibited polyomavirus replication in a dose-dependent manner 
by blocking the synthesis of viral DNA in an in vitro system 
(Berardi, V. et al., 2009). A strong antiviral activity of resveratrol 
has been also demonstrated against infl uenza virus in vitro and 
in vivo (Palamara, A.T et al., 2005). As observed for HSV-1 and 
polyomavirus, resveratrol treatment did not cause virus particle 
inactivation or inhibition of viral adsorption but induced a decrease 
in the translation of late viral proteins. Recently, Zang et al. (2011) 
provided evidence that resveratrol was a potent suppressor of 
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Respiratory Syncytial Virus (RSV) infection, infl ammation, and the 
airway hyperresponsiveness (AHR) response associated with RSV 
infection. However, resveratrol signifi cantly enhanced Hepatitis 
C virus (HCV) replication making it unsuitable for an antioxidant 
therapy in chronic hepatitis C (Nakamura M et al., 2010).
16
1.4 Epstein Barr Virus (EBV)
EBV, known as the causative agent of infectious mononucleosis, 
is a member of the Herpesviridae family. Like other herpesviruses, 
EBV is an enveloped virus that contains a DNA core surrounded 
by an icosahedral nucleocapsid and a tegument. Family members 
include herpes simplex I and II and varicella-zoster virus 
(alphavirus subfamily), cytomegalovirus and human herpesvirus 6 
and 7 (betaherpesvirus subfamily), and human herpesvirus 8 and 
EBV (gammaherpesvirus subfamily; Roizman, B 1990). Human 
tumors have been attributed to both human herpesvirus 8 (Kaposi’s 
sarcoma, primary effusion lymphoma, and Castleman’s disease) 
and to EBV. Up to date, tumors related to EBV infection include 
Burkitt’s lymphoma (BL), nasopharyngeal carcinoma (NPC), 
Hodgkin’s (HD) and non-Hodgkin’s lymphomas, gastric cancer, 
breast cancer, leiomyosarcomas arising in immunocompromised 
individuals, central nervous system lymphomas associated with 
HIV, post-transplant lymphoproliferative disorders (PTLDs). 
The B-lymphotropic nature of EBV is evidenced by the ability of 
the virus to immortalize normal resting B lymphocytes in vitro, 
converting them into permanently growing lymphoblastoid cell 
lines (Nilsson, K 1992).
Two subtypes of EBV are known to infect humans: EBV-1 and EBV-
2. They differ in the organization of the genes that code for the EBV 
nuclear antigens (EBNA-2, EBNA- 3a, EBNA-3b, and EBNA-3c; 
Sample, J. et al., 1990). EBV-2 transforms B cells less effi ciently 
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than EBV-1 in vitro, and the viability of EBV-2 lymphoblastoid 
cell lines is less than that of EBV-1 lines (Buisson, M. et al., 1994). 
The differences in transforming effi ciency of the EBV subtypes 
may relate to divergence in the EBNA-2 sequences (Cohen J et al., 
1989, Rickinson A. et al., 1987).
EBV-1 and EBV-2 differ in geographic distributions. EBV-1 is 
observed more frequently in most populations. However, EBV-
2 is nearly as prevalent as EBV-1 in New Guinea, as well as in 
equatorial Africa (Young, L. S et al., 1987; Sixby, J. W. 1989). 
Endemic Burkitt’s lymphoma and holoendemic malaria are 
common in equatorial Africa, and it has been shown that almost 
half of all African Burkitt’s lymphoma tumors carry EBV-2. In 
contrast, 85% of nasopharyngeal carcinomas in Taiwan contain 
EBV-1 (Shu, C. H. et al., 1999). Immunocompromised patients 
also more commonly harbor both subtypes of EBV (Borisch, B. 
et al., 1992). Taken together with the attenuated transforming 
ability of EBV-2, these data suggest that it may be necessary a 
preexisting immunosuppressed condition (HIV or malaria) for 
EBV-2 B-lymphocytic infection and transformation (Buisson, M. 
et al., 1994).
1.4.1 Molecular Biology of EBV
EBV is an herpesvirus with a 184-kbp long, double-stranded DNA 
genome that encodes about 100 proteins (Kieff E., and Rickinson 
A. B 2001). The viral genome carries two 0.5-kb terminal repeats 
at either end and internal repeat sequences, resulting into short 
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and long unique sequence domains that have most of the coding 
capacity (Cheung, A., and Kieff, E 1982). Similar to other 
herpesviruses, EBV has a toroid-shaped protein core containing 
the DNA, a nucleocapsid with 162 capsomeres, a protein tegument 
between the nucleocapsid and envelope, and an outer envelope 
with external glycoprotein spikes (Rickinson, A. B., and Kieff E 
2001). After infection, the EBV DNA becomes a circular episome 
with a characteristic number of terminal repeats, depending on the 
number of those in the parental genome, with variation introduced 
during viral replication. If the infection is permissive for latent 
infection but not replication, future generations will have EBV 
episomes with the same number of terminal repeats. Therefore, the 
number of terminal repeats in a group of latently infected cells can 
be useful in eludicating if these cells arose from a single cancer-
infected progenitor or from multiple progenitors (Baumforth, K. R. 
N et al., 1999).
1.4.2 EBV Infection
Although herpesviruses are ubiquitous in nature, humans are the 
only natural host for EBV. It is now known that EBV infects > 
90% of the world’s adult population. Upon infection, the individual 
remains a lifelong carrier of the virus (Henle G. et al., 1979).
EBV is transmitted from host to host via saliva. Primary infection 
begins at the oropharyngeal epithelium. B lymphocytes are 
infected when they are in proximity to these cells. During acute 
infection, EBV expresses proteins that induce cell proliferation in 
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B lymphocytes. An EBV-specifi c CTL response occurs in healthy 
people and probably is responsible for the decrement in infected B 
cells from levels as high as 10% in acute EBV infection to 1 in 106 
cells with convalescence. In a primary EBV infection, three classes 
of antibodies (-IgG, -IgM, and -IgA) are produced against EBV 
viral capsid antigen, two (-IgG and -IgA) are produced in response 
to early antigen D, and one (-IgG) is produced in response to early 
antigen R (Linde A. 1996). During a latent infection, EBNA-3A, 
EBNA-3B, and EBNA-3C all elicit specifi c CTL responses, the 
dominant latency response to EBV proteins (Tan, L. C. et al., 1999; 
Murray, R. J et al., 1992; Khanna, R. et al., 1992). EBV infection of 
B cells begins with the attachment of the gp 350/220 viral membrane 
glycoprotein to the CD21 molecule on these lymphocytes (Nemerow 
G. et al., 1985). CD21 becomes cross-linked, triggering an initial 
signal able to prepare the cell for EBV infection. EBV binding 
to CD21 immediately activates tyrosine kinase lck and mobilizes 
calcium (Cheung, R., and Dosch, H 1991; Gordon, J. et al., 1986). 
This event is followed by an increment in mRNA synthesis, blast 
transformation, homotypic cell adhesion, surface CD23 expression 
(a characteristic marker for activated B cells), and interleukin (IL)-
6 production (Tanner J. et al., 1987, 1996; Alfi eri C. et al., 1991). 
The virion is then uncoated and the viral DNA is transported into 
the nucleus where it immediately circularizes. Circularization and 
W promoter expression promote an ordered cascade of events that 
leads to the expression of all of the EBNA proteins and the two 
latent membrane proteins (LMPs; Allday M. et al., 1989). The EBV 
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nuclear antigen leader protein (EBNA-LP) and EBNA-2 proteins are 
the fi rst proteins to be detected upon EBV infection (Hennessy, K., 
and Kieff, E 1985). EBNA products are involved in transcriptional 
control and participate in the activation of the expression of the 
viral LMP-encoding genes (LMP-1 and LMP-2) and several 
cellular genes. The combined action of these viral and cellular 
proteins stimulates cellular S-phase 24–48 h after infection (Rowe, 
D 1989). The viral genome is generally episomal and present in low 
numbers in the host cell’s nucleus. Immunosuppressive states favor 
spontaneous replication of the viral episome in circulating B cells, 
as observed in acute infectious mononucleosis. Loss of the EBV-
specifi c CTL may permit the development of lymphoma. Besides 
its well-known tropism for B cells, EBV also infects epithelial 
cells, T cells, and cells of the macrocytic, granulocytic, and natural 
killer lineages. These cells may be infected by different mechanism 
from the CD21-mediated internalization typical in B cells.
1.4.3 EBV latent products
EBV encodes a number of products that interact with or 
exhibit homology to a wide variety of antiapoptotic molecules, 
cytokines, and signal transducers, thus promoting EBV infection, 
immortalization, and transformation. During the latent phase, 
EBV expresses a limited set of viral gene products, consisting 
of six nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, 
EBNA3C, and EBNA leader protein (EBNA-LP)), three latent 
membrane proteins (LMP1, LMP2A, and LMP2B) and two small 
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non-polyadenylated (and therefore non-coding) RNAs (EBER 
1 and 2). The function of EBERs transcripts is not clear but they 
are consistently expressed in all forms of latent EBV infection.
Figure 2. 
Some of the functions of the EBV-encoded proteins expressed in latent infection 
of B-lymphocytes. (Klein G. et al., 2010)
1.4.4 Patterns of EBV Gene Expression
All EBV-associated cancers involve the viral latent cycle. Three 
types of latent gene expression have been described and characterize 
a heterogenous group of malignancies (Table 2). During latency 
I, EBNA-1 and the EBERs are expressed. Latency I is generally 
associated with the EBV-related malignancy Burkitt’s lymphoma 
(Sbih-Lammali, F.et al., 1996). Latency II has been associated 
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with Hodgkin’s disease, T-cell non-Hodgkin’s lymphoma, and 
nasopharyngeal carcinoma (Cesarman, E., Mesri, E. A. 1999). 
EBV gene expression in latency II is usually limited to EBNA-
1, the EBERs, LMP-1, and LMP-2A and LMP-2B (Liebowitz, D., 
and Kieff, E. 1993). The fi nal pattern of gene expression (latency 
III) occurs mainly in immunocompromized individuals affl icted 
by post-transplant lymphoproliferative disorders (PTLDs), AIDS-
related proliferative disorders, and in lymphoblastoid cell lines 
(LCLs) (Niedobitek, G. et al., 1997). Latency III usually involves 
the expression of all EBNAs, EBERs, and LMPs (Liebowitz, D., 
and Kieff, E. 1993). 
Table 2. 
EBV latency pattern and associated malignancies. (Matthew P. Thompson and 
Razelle Kurzrock. 2004)
1.4.5 Oncogenic Features of EBV
To be oncogenic, EBV must maintain its viral genome in the 
cell, establishing latent infection in B lymphocytes. The EBV 
genome is maintained in these cells, either as a multicopy circular 
Latency type Viral genes expressed Associated malignancies
Latency I EBNA-1
EBERs
Burkitt ’ s lymphoma
Latency II EBNA-1
EBERs
LMP-1
LMP-2
Hodgkin ’ s disease
Nasopharyngeal carcinoma
Peripheral T/NK lymphoma
Latency III All EBNAs
EBERs
LMP-1
LMP-2
AIDS-associated lymphomas
Posttransplant lymphoproliferative disord
Lymphoblastoid cell lines
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episome or by integrating the viral DNA into the cellular genome. 
In normal individuals, cytotoxic T-cell responses against latent 
viral proteins prevent the expansion of these activated B cells. 
Through normal differentiation of these cells, EBV arrives in the 
resting B-cell memory compartment. In these lymphocytes EBV 
expresses only EBNA-1 and escapes immune surveillance because 
cytotoxic responses against this viral latent protein are rare. 
Intermittently, these cells may enter the lytic cycle with subsequent 
lysis/death of infected cells, releasing virions to infect more cells. 
In a state of immunosuppression, latently infected cells in the 
peripheral blood or persistently infected cells on the oropharynx 
increase in number. Through diverse virally expressed genes that 
stimulate multiple intersecting cellular transduction pathways, 
involved in control of proliferation, EBV can become oncogenic. 
LMP1 is the main latent viral product with oncogenic features.
EBNA-1
EBNA-1 is a sequence-specifi c DNA binding phosphoprotein 
that is required for the replication and maintenance of the EBV 
genome (Middleton, T., and Sugden, B. 1994). EBNA-1 binds to 
the origin of latent plasmid replication (oriP), which is composed 
of two distinct EBNA-1 binding elements (Ambinder, R. et 
al., 1990). These are the family of repeats (FRs) and the dyad 
symmetry (DS). The family of repeats and the dyad symmetry 
binding elements both contain multiple 18-bp EBNA-1 binding 
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sites (Wysokenski, D., and Yates, J 1989). The family of repeats 
element contains 20 binding sites, whereas the dyad symmetry 
element only contains 4 EBNA-1 binding sites. Following EBNA1 
binding to the plasmid origin of replication, EBV uses host enzymes 
to mediate all remaining steps in replication. EBV episomes are 
present at low copy numbers and replicate only once per cell cycle. 
Their maintenance at a stable copy number in dividing cells also 
requires a mechanism to ensure segregation during cell division. 
The mitotic segregation or partitioning of the EBV episomes 
depends on EBNA1 and the oriP FR elements. EBNA1 functions by 
tethering the EBV episomes to the cellular chromosomes in mitosis 
and the pairing of EBV episomes on sister chromatids ensures their 
equal distribution to the daughter cells (Delecluse HJ. Et al., 1993).
LMP-1
LMP-1 is involved in transformation by acting as a constitutively 
active receptor (CD40), thus miming the cellular growth signal that 
normally results from the binding of CD40 ligand (Zimber-Strobl, 
U et al., 1996; Gires, O. et al., 1997). LMP-1 has been most directly 
linked to oncogenesis because of its ability to recruit a number of 
cellular genes. It also inhibits apoptosis by elevating levels of Bcl-
2 (Zimber-Strobl, U et al., 1996). LMP-1 is an integral membrane 
protein with six hydrophobic membrane-spanning segments 
and a COOH-terminal cytoplasmic tail, representing the effector 
(Farrell, P. J 1998). LMP-1 aggregates in patches on the plasma 
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membrane (Clausse, B. et al., 1997) and mutational analyses 
have demonstrated that the N-terminal and the trans-membrane 
segments of LMP-1 are responsible for membrane aggregation 
and that this aggregation is essential for immortalization (Moorthy, 
R., and Thorley-Lawson, D 1993). LMP-1 simulates CD40 by 
associating with the same tumor necrosis factor receptor-associated 
factors (TRAFs; Eliopoulos, A. et al., 1996). The COOH-terminal 
domain of LMP-1 interacts with TRAFs and with tumor necrosis 
factor receptor-associated death domain protein through different 
regions known as transformation effector sites (Thompson MP. et 
al., 2003; Izumi, K., and Kieff, E. 1997). At least four signaling 
pathways, namely NF-kB, c-Jun N-terminal kinase s (JNKs), 
p38 MAPK, and Janus kinase (JAK)/signal transducers and 
activators of transcription (STATs) are implicated in the function 
of LMP-1 (Huen DS. et al., 1995; Eliopoulos AG. et al., 1998, 
1999; Gires O.et al., 1999). The activating cascades associated 
with LMP-1 lead to the enhanced expression of B-cell adhesion 
molecules (LFA1, CD54, and CD58), enhanced expression of 
B-cell activation markers (CD23, CD39, CD40, CD44, and HLA 
class II), and morphological changes such as cellular clumping 
(Zimber-Strobl U. et al., 1996, Izumi, K., and Kieff, E. 1997, 
Martin J et al., 1993; Wang, D. et al., 1988;Wang, F.et al., 1990). 
1.4.6 EBV-associated Cancers
EBV, the fi rst human tumor virus discovered, has been implicated 
in the development of a wide range of cancers (Table 3).
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Table 3. 
Characterization of EBV-associated malignancies. (Matthew P. Thompson and 
Razelle Kurzrock. 2004) 
Burkitt’s Lymphoma
In 1958, Denis Burkitt (Burkitt, D. P 1958) described a common 
cancer in children of specifi c regions of Africa. Burkitt believed a 
virus might be responsible for the cancer, given the climatic and 
geographic distribution of the cases. EBV was fi rst identifi ed in 
1964 when Anthony Epstein’s group observed virus-like particles 
by electron microscopy in a cell line that had been established from 
a Burkitt’s lymphoma biopsy (Epstein, M. A. et al., 1964). Later, 
it was found that sera from patients with the Burkitt’s lymphoma, 
had much higher EBV antibody titers than controls without the 
lymphoma. The subsequent detection of EBV DNA in Burkitt’s 
Malignancy Subtype EBV gene expression pattern
Burkitt’s lymphoma Endemic
Nonendemic
Latency I
Hodgkin’s disease MC
LD
NS
LP
Latency II
Non-Hodgkin’s lymphoma Nasal T/NK
Angioimmunoblastic
Lymphadenopathy
Latency II
Latency II
Nasopharyngeal carcinoma Anaplastic Latency II
Breast Cancer Medullary carcinoma
Adenocarcinoma
Not clear
Gastric Cancer Lymphoepithelioma-like
Adenocarcinoma
Controversial novel LMP1 (-)
Latency III
PTLDs Latency III
AIDS-associated lymphomas IP-CNS
Other
Latency III
Leiomyosarcomas in
immunosuppressed individuals
UnclearLeiomyosarcomas varies
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lymphoma and the experimental production of lymphomas in 
animal models established EBV as the fi rst virus clearly implicated 
in the development of a human tumor (Epstein, M. A. et al., 1964).
Burkitt’s lymphoma is a particularly aggressive lymphoma, 
characterized by a chromosomal translocation between chromosome 
8 and either chromosomes 14, 2, or 22 (Gulley, M. L 2001; Manilov, 
G et al., 1986; Dalla-Favera, R. et al., 1982; Taub, R. et al., 1982). 
Because of this translocation, the oncogene c-myc (chromosome 
8) is juxtaposed to the immunoglobulin heavy-chain (chromosome 
14) or light-chain genes (chromosomes 2 or 22), resulting in the 
deregulation of its own expression. The relationship between EBV, 
Burkitt’s lymphoma, and the c-myc translocation is complicated by 
the existence of two types of Burkitt’s lymphoma: endemic (EBV 
positive) and non endemic (generally EBV-negative). They differ 
in the breakpoints within the genes involved and presumably in 
the mechanism mediating juxtaposition (Baumforth, K. R. N et al., 
1999). Endemic Burkitt’s lymphoma occurs primarily in equatorial 
Africa and Papua New Guinea, with EBV being present in > 90% 
of cases (Lenoir, G. et al., 1984). The role of EBV in Burkitt’s 
lymphomas is strongly supported by observations of the Akata 
Burkitt’s lymphoma cell line. Akata subcultures that have lost 
EBV have decreased growth and have not induced tumors in mice 
(Shimizu N. et al., 1994). Reinfection of the Akata cells with EBV 
reestablishes the malignant phenotype (Komano, J. et al., 1998). 
Non endemic Burkitt’s lymphoma is found in the West and its 
incidence has increased dramatically because of its high prevalence 
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in AIDS patients. Only 15–30% of non endemic Burkitt’s lymphoma 
cases are associated with EBV in the United States (Subar, M. et al., 
1998), however, the percentage is 85% in Brazil. As with malaria 
in endemic Africa, coinfection is thought to increase the oncogenic 
potential of the B cell (Araujo, I. et al., 1996). 
EBV-associated Lymphomas in Immunocompromised Individuals
Several distinct classes of EBV-associated lymphoproliferative 
disorders exist in immunocompromised individuals. Among them, 
there are lymphomas associated with immunosuppressive drugs 
given to transplant recipients, and AIDS-related lymphoproliferative 
disorders. The most common gene expression pattern in these 
disorders is latency III. Mostly, EBV-associated lymphomas in the 
immunocompromised patients are aggressive and diffi cult to treat.
Posttransplant Lymphoproliferative Disorders (PTLDs)
These heterogeneous lymphoproliferative disorders occur in the 
setting of therapeutic immunosuppression after organ transplantation 
(Cesarman, E., Mesri, E. A. 1999). This condition, leading to primary 
EBV infection or reactivation of latent EBV infection, is followed 
by polyclonal expansion of B-cell populations with a selective 
growth advantage. These cells are susceptible to genetic changes 
and other molecular aberrations that drive malignant growth. The 
incidence of post-transplant lymphoproliferative disorders ranges 
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from 0.5 to 30%, depending on the organ being transplanted, the 
EBV status of the transplant recipient and donor, and the therapies 
used to obtain immunosuppression (Knowles, D. M 1998). A variety 
of distinct post-transplant lymphoproliferative disorders have 
been described, including plasmacytic hyperplasia, polymorphic 
lymphoproliferative disorder, malignant non-Hodgkin’s lymphoma, 
and multiple myeloma (Knowles, D. M 1998). Most posttransplant-
lymphoproliferative disorders are B-cell neoplasms. PTLDs arising 
in bone marrow transplant recipients are generally of donor origin, 
whereas those in solid organ recipients are usually of recipient 
origin. The diagnosis and monitoring of patients affected by these 
diseases (Gulley, M. L 2001), revealed correlation between PTLDs 
and EBV viral load measured by quantitative PCR of the peripheral 
blood. 
AIDS-Related Lymphoproliferative Disorders
AIDS-related lymphoproliferative disorders arise in the presence 
of HIV-associated immunosuppression that permits the unchecked 
proliferation of EBV-infected lymphocytes. These disorders 
include both central nervous system and systemic lymphomas. 
AIDS-related central nervous system lymphomas are derived 
from germinal center B cells and (Cesarman, E., Mesri, E. A. 
1999) include immunoblastic and large lymphomas. The AIDS-
related systemic lymphomas include diffuse large cell lymphomas, 
immunoblastic lymphomas, Burkitt’s lymphomas, and small, 
Burkitt’s-like lymphomas. EBV positivity for these lymphomas 
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ranges from 30 to > 90% (Cesarman, E., Mesri, E. A. 1999, Davi, 
F. et al., 1998; Shibata, D. et al., 1993).
1.4.7 Treatment
Despite the growing understanding of the role of EBV in the 
pathogenesis of disease, the control of EBV remains unsatisfactory 
and novel therapeutic approaches are explored.
There are several antiviral compounds that have entered the 
clinical setting and have some anti-EBV activity. However, it has 
been diffi cult to demonstrate reproducible antitumor effects. The 
majority of these drugs are broad-spectrum anti-herpesvirus and 
anticytomegalovirus agents that vary in their effectiveness against 
EBV. They include ganciclovir, famcyclovir, acyclovir, valaciclovir 
(a prodrug of acyclovir), foscarnet, and cidofovir. Moreover, a 
variety of non conventional compounds may have antiviral effects. 
For instance, fl avanones (amorilin and lupinifolin) from plant 
extracts block EBV early antigen activation in vitro (Itoigawa, M. 
et al., 2002). Additionally, fl avonoid derivatives synthesized from 
morin and quercetin and several herbal remedies may have varying 
degrees of anti-EBV activity (Iwase, Y. Et al., 2001, Kapadia, G. et 
al., 2002). The drawback of antivirals is that they have no effect on 
the latent EBV infection .
Adoptive immunotherapy, using EBV-specifi c CTLs, may 
overcome this problem (Gottschalk, S. et al., 2002). CTLs may 
be isolated from the recipient’s own lymphocytes, expanded in 
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vitro, and infused back into the patient. This approach has been 
proven effective in the treatment of PTLD (Heslop et al., 2010), but 
unsuccessful in patients with NPC or HD. 
Many studies have been directed to develop an EBV vaccine that 
would be used  both for  preventive as well as therapeutic purposes. 
Vaccination with recombinant gp350 viral glycoprotein or CTL 
epitope-based peptides have been successful in generating viral 
immunity in animal models (Jackman WT et al., 1999) and clinical 
vaccine trials in healthy individuals demonstrated the appearance 
of neutralizing anti-EBV antibodies in vaccinated individuals 
(Moutschen M et al., 2007). Another therapeutic approach is based 
on antibodies directed against B-cell antigens, such as CD20 to 
obtain the depletion of EBV-infected B-cells. The anti-CD20 
monoclonal antibody designated Rituximab has been effi ciently 
used in the treatment of a variety of CD20-expressing lymphomas as 
well as of EBV-related lymphoproliferative disorders and PTLDs. 
However, rituximab treatment is unsuitable for immunosuppressed 
patient since normal B cells are also destroyed increasing the risk 
of concomitant infections (Lee MY et al., 2007). 
In the last years, attempts have been made to use antiviral compounds 
in conjunction with drugs that can induce lytic replication through 
epigenetic modifi cations with valproic acid or SAHA (Vorinostat), 
both histone deacetylase inhibitors. Azydothymidine (AZT), 
bortezomib, gemcitabine, and doxorubicin can also induce lytic 
replication and expression of viral thymidine kinases, so their 
use in combination with other treatment modalities has also been 
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proposed as a form of oncolytic therapy. These approaches have 
shown results in experimental systems, but results from clinical 
trials have not been published.
1.4.8 EBV and lytic cycle
The latency to lytic switch has implications for the pathogenesis 
of EBV-associated malignant and non malignant diseases. While 
latency may be the predominant life cycle form in virus-associated 
cancers, the virus must replicate in order to be transmitted between 
cells and among individuals. This lytic phase of infection is 
clinically associated with infectious mononucleosis and oral hairy 
leukoplakia (Rickinson and Kieff, 2007). The cascade of events in 
the lytic phase of the EBV life cycle is divided into three phases 
of regulated gene expression: immediate–early (IEA), early (EA) 
and late (LA) antigens. Although the latency to lytic cycle switch 
can be manipulated in cell culture, by the addition of one or more 
chemical-inducing agents, little is understood about the physiologic 
event in vivo. The stimulus may be external, for example ralterations 
of activating or inhibitory signals, or may be internal, refl ecting 
the metabolic state of the cell and its position in the cell cycle.
33
Figure 3. 
Switch from latent to lytic cycle.
Virally encoded lytic cycle activator genes (IEA) 
ZEBRA, encoded by the viral BZLF1 gene, is a member of the basic 
zipper (bZIP) group of transcriptional activators like mammalian 
cellular members c-Fos and c-Jun. ZEBRA binds to canonical AP-1 
sites as well as ZEBRA response element (ZRE) in promoters of 
viral and cellular genes and activates their transcriptions. ZEBRA 
is essential to activate lytic cycle genes (Feederle et al., 2000), 
in particular the expression of another transcription factor, Rta, 
encoded by the viral BRLF1 gene (Kolman et al., 1996). ZEBRA 
and Rta then act in synergy to activate transcription of early lytic 
cycle genes many of them required for lytic viral DNA replication 
(Quinlivan et al., 1993; Ragoczy and Miller, 1999). However, Rta 
seems to be able of activating a distinct set of viral genes independent 
of ZEBRA (Chen et al., 2005; Ragoczy and Miller, 1999). ZEBRA 
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represses the action of Rta on some promoters in a temporally 
controlled manner (El-Guindy and Miller, 2004; Ragoczy and 
Miller, 1999). ZEBRA is involved in viral lytic DNA replication 
by binding to the origin of lytic cycle replication (oriLyt) and by 
interacting with and recruiting viral proteins that are essential for 
lytic replication (Baumann et al., 1999; Fixman et al., 1992; Gao et 
al., 1998; Lieberman et al., 1990; Schepers et al., 1993, 1996).
During latency the BZLF1 and BRLF1 genes are probably repressed 
by epigenetic mechanisms such as chromatization and DNA 
methylation of the BZLF1 promoter, Zp, and BRLF1 promoter, 
Rp, as well as occupancy of these promoters by specifi c repressors. 
Following application of an inducing stimulus, cellular activators 
,such as Sp1, c/EBPα, AP-1, and CREB, likely bind to Zp and Rp. 
These cellular factors lead to low-level expression of ZEBRA and 
Rta, which then amplify the signal by autostimulating and cross-
stimulating each other’s expression. Rta autostimulates Rp by an 
indirect mechanism that involves interaction with other proteins 
such as those of the Sp1 family (Ragoczy and Miller, 2001). Rta may 
infl uence the activity of cellular transcription factors by protein–
protein interactions and by activating signaling cascades that lead 
to posttranslational modifi cation of the cellular transcription factors 
(Adamson et al., 2000).
ZEBRA and Rta synergistically activate expression of many 
downstream viral target genes, resulting in synthesis of early 
antigen (EA) and late antigens (LA), with the fi nal production of 
the progeny virus.
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Functions of the main early antigens (EA)
BALF5
After induction of viral productive replication, the EBV genome is 
amplifi ed 100-1,000-fold by viral replication machinery composed 
of BALF5 DNA polymerase, BMRF1 polymerase processivity 
factor, BALF2 single-stranded DNA-binding protein, and BBLF4-
BSLF1-BBLF2/3 helicase-primase complex in replication 
compartments in the nucleus (Daikoku, T et al., 2005; Fixman, E. 
D. et al., 1995). BALF5 possesses intrinsic DNA polymerase and 
3’-to-5’ exonuclease activities (Tsurumi, T et al., 1994) and forms a 
complex with the BMRF1 polymerase accessory protein increasing 
its processivity (Tsurumi, T 1993). 
BFRF1 and BFLF2
One common feature shared by several viruses during the 
envelopment process to exit from the nucleus is the modifi cation of 
the nuclear envelope structure. The nuclear envelope is composed 
of the outer and inner nuclear membranes and fi lamentous proteins 
called lamins, attached to the nuclear membrane by integral 
membrane proteins and collectively forming the nuclear lamina. 
For herpesviruses, dismantling of the nuclear lamina during HSV-
1 infection has been reported by Scott and O’Hare (Scott, E. S., 
and P. O’Hare 2001), and a similar effect has been attributed to 
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protein kinase C (PKC)-mediated phosphorylation of the nuclear 
lamina induced by the BFRF1 and BFLF2 homologs during mouse 
cytomegalovirus infection (Muranyi, W et al., 2002). Gonnella R et 
al. (2005) reported the association of the BFRF1-BFLF2 complex 
with lamin B at the nuclear membrane, showing the possible 
involvement of these proteins in affecting nuclear lamina structure 
and function. In addition, an interesting observation is represented 
by the profound nuclear alterations induced by expression of BFRF1 
and even more by BFRF1/BFLF2 coexpression, thus suggesting 
the involvement of the two viral products.
Viral homologues of anti-apoptotic members of the BCL-2 family
Herpesviruses are known to encode homologues of cellular anti-
apoptotic BCL-2 proteins, which protect the infected host cell from 
apoptosis during viral synthesis (Boya et al., 2004). EBV even 
encodes two viral BCL-2 proteins, BHRF1 and BALF1, highly 
expressed within the fi rst 24 h post infection, hardly detectable in 
latently infected cells and again maximally expressed during the 
lytic cycle. Genetic analyses demonstrated that primary resting 
human B cells infected with a Bcl-2-negative EBV did not enter 
the cell cycle and died of immediate apoptosis. Moreover, the 
inactivation of these genes disabled EBV’s capacity to transform 
the primary B cells but did not negatively affect virus de novo 
synthesis in established, latently infected cells (Altmann and 
Hammerschmidt, 2005). The expression of the two viral BCL-2 
37
proteins were previously thought to be induced by BZLF1, during 
EBV’s lytic phase. However, the early expression of viral Bcl-2 
genes in the early phase of infection (Altmann and Hammerschmidt, 
2005) suggests that their expression may be also not regulated by 
BZLF1 activation. 
1.4.9 Lytic program reactivation in vitro
In latently infected cells, the induction of the lytic phase of 
EBV’s life cycle can be achieved by different compounds in vitro. 
12-O-tetradecanoylphorbol-13-acetate (TPA) is able to trigger the 
reactivation of EBV through PKC signaling pathway (Baumann M. 
et al., 1998), while transforming growth factor beta 1 (TGF-beta1) 
stimulates MAPK cascade (Fahmi H. et al., 2000). Finally, histone 
deacetylase (HDAC) inhibitors promote the switch from latent to 
lytic phase in PKC independent manner, leading to the derepression 
of silenced promoters and subsequent changes in gene expression 
(Jenkins P.J. et al., 2000). All these agents activate expression of the 
viral immediate-early protein BZLF1.
Of the different ways to reactivate the lytic program in vitro, 
treatment with anti-Ig antibodies seems to be more physiologically 
relevant since it mimics B-cell antigen-receptor (BCR) signaling 
(Iwakiri and Takada, 2004; Takada, 1984; Tovey et al., 1978). Upon 
antigen binding, BCR aggregates and activates protein tyrosine 
kinases Lyn, a member of Src family of tyrosine kinases, and Syk. 
Simultaneously, antigen binding causes activation of PI3K (through 
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BCR co-receptor CD19), which, along with Lyn and Syk, is 
involved in activation of Bruton’s tyrosine kinase (Btk). Once Lyn, 
Syk, and Btk are activated, the signal is further propagated through 
activation of phospholipase Cc2 (PLCc2). PLCc2 hydrolyzes 
phosphatidylinositol diphosphate (PIP2) into diacylglycerol 
(DAG) and inositol triphosphate (IP3). IP3 generation causes the 
mobilization of Ca2+ ions required for the activation of several 
transcription factors (such as NF-kB), whereas DAG activates 
conventional protein kinase C (PKC) isotypes which regulate 
MAPK family. Following activation, these kinases phosphorylate 
different sets of transcription factors, which then regulate expression 
of certain genes. Other similar ‘downstream’ effectors are Akt 
and Ca2+-calmodulin. A number of studies demonstrated that 
activation of PI3K, PKC, MAPK, and NF-kB pathways is crucial 
for activation of EBV lytic program (Daibata et al., 1990; Darr et 
al., 2001; Davies et al., 1991; Gao et al., 2001; Iwakiri and Takada, 
2004; Lazdins et al., 1987; Mori and Sairenji, 2006; Oussaief et 
al., 2011; Satoh et al., 1999); however, other reports suggested that 
inhibition of PI3K or NF-kB pathways facilitates reactivation of 
lytic program of several gammaherpesviruses (Brown et al., 2003; 
Liu et al., 2008; Peng et al., 2010).
Superinfection of latently infected cells with EBV defective 
substrains or ectopic expression of viral immediate early genes are 
also methods used to promote reactivation in vitro (Takada K. e 
Ono Y., 1989; Adamson A.L. e Kenney S.C., 1998).
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2. Aim of the project
Resveratrol is a potent chemopreventive agent with in vivo and in 
vitro proved effi cacy against a broad spectrum of malignant cells 
and among them, it has been reported that can inhibit the growth 
of malignant B-cell lines in a dose- and time-dependent manner 
(Gupta SC et l., 2010, 2011). 
As described above, EBV infects B cells and transforms them by 
subverting multiple cellular pathways that control proliferation and 
apoptosis. However, the virus, during the latent phase of infection 
established in most of EBV-related malignancies, differentially 
expresses its antigens that may vary from one (latency I), to nine 
(latency III).  Recently it was reported that different Burkitt’s 
lymphomas express different combinations of EBV antiapoptotic 
genes indicating that the virus contributes survival functions of 
these tumors in multiple ways. We hypotesized that EBV-related 
tumors that vary for the  pattern of  viral antigens expressed might 
show distinctive responsiveness to the antiproliferative activity of 
resveratrol. 
One goal of this project was therefore to assess whether resveratrol 
would be able to inhibit the growth of malignant B cells in which 
EBV infection might confer additional survival potential, also 
depending on the different programs of latent gene expression 
adopted by the virus. 
To this end, in the same cellular background, I have investigated the 
contribution that different patterns of EBV gene expression give 
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to resveratrol-induced susceptibility to apoptosis and studied the 
molecular mechanisms underneath. In particular, the role played 
by the viral oncogene LMP1 and strategies to down-regulate its 
expression, have been examined. 
EBV productive cycle allows horizontal spread of the virus and 
favors B cell tumors development. Moreover, large amounts of 
virus are produced in infectious mononucleosis (IM) and hairy 
leucoplakia (HLP) of the tongue, in AIDS patients.
Therefore, the second goal of this project was to evaluate the activity 
of resveratrol against EBV replication. For this purpose, I have 
examined the effects of the polyphenol in two Burkitt’s lymphoma 
cell lines where is possible to activate EBV lytic cycle by treating 
the cells with different inducing agents. In particular, in cross-
linked Akata cells, a system for EBV activation that most likely 
mimics the mechanism of viral reactivation in vivo, I evaluated 
the effects of resveratrol on EBV lytic genes expression and viral 
particles production. Drug targets that might affect EBV replicative 
activity, have been studied.  
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3. Materials and Methods
3.1 Reagents
Resveratrol (Sigma), prepared a 50 mg/ml stock solution in 
ethanol and kept at 20°C protected from light, was diluted to fi nal 
concentrations in RPMI 1640 medium. Cycloheximide (CHX) 
purchased from Sigma, was dissolved in DMSO at 100 mg/ml and 
used at 50 μg/ml.
3.2 Cell culture and treatment with resveratrol
Human Burkitt’s lymphoma (BL)-derived cell lines, either positive 
or negative for EBV, and human B lymphoblastoid cell lines were 
used. EBV-positive Raji and EBV(-) Ramos cells were purchased 
from American Type Culture Collection (LGC Promochem). Akata 
with the EBV genome (Takada K 1984;Takada K, Ono Y. 1989), 
the isogenic EBV(-) Akata subline 2A8 (Shimizu N, et al., 1994), 
and Jijoye M13 cells (Minarovits J. et al., 1991) were obtained from 
Dr. P. Trivedi (Sapienza University, Rome, Italy). Lymphoblastoids 
LCL1087 and LCL1260 were gifts from Dr. R. Dolcetti [Cancer 
Bioimmunotherapy Unit, Aviano (PN), Italy]. All cell lines were 
cultured in RPMI-1640 medium containing 10% fetal calf serum 
(FCS) and antibiotics in a 5% CO2 atmosphere and maintained 
at a cell density of 3.5 x 105/mL. Cells, at a density of 3 x 105 
cells/mL, were incubated in RPMI-1640/10% FCS with different 
concentrations of resveratrol (Sigma) from a stock solution of 50 
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mg/mL dissolved in ethanol and kept at 20°C protected from light. 
Control cells were treated with the diluent. At different times, viable 
cells excluding Trypan blue dye were counted in a Burker chamber. 
The percentage of proliferation was determined as proliferation of 
treated cells x 100/proliferation of untreated cells.
3.3 EBV lytic cycle induction
EBV-positive Raji cells, characterized by a latency III pattern and 
an EBV abortive lytic cycle and Akata cells showing a latency I 
phenotype, were used. To induce EBV lytic cycle, Raji cells (1.5 x 
107) were electroporated with 10 μg of pCMVgenZ (a kind gift of 
Dr. G. Miller, Yale University School of Medicine, USA) using a 
Bio-Rad Gene Pulser (0.26 kV and 960 μF) and thereafter diluted 
to 5x105 /ml. Control Raji cells were electroporated with 10 μg 
of the CMV vector. To activate the virus in Akata cell line, cells 
were diluted to 106 /ml and treated with 10 μg/ml of goat anti-
human IgG (Sigma, St.Louis, MO, USA).The effi ciency of EBV 
lytic cycle induction was evaluated, in both cell lines, by counting 
positive cells after immunofl uorescence staining with FITC-labeled 
antibodies specifi c for EBV early antigens (Matusali et al., 2009). 
Statistical analysis of the cells expressing EA revealed that in Raji 
as well as in Akata cells, EBV lytic cycle was activated in about 
30% of the cell population, regardless of the method used to initiate 
the process.
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3.4 Cytofl uorimetric analysis
Cell-cycle studies were conducted by fl uorescence-activated cell-
sorting (FACS) analysis after DNA staining with propidium iodide 
(PI). Cell samples were washed with phosphate buffer saline (PBS) 
and centrifuged for 5 min at 300 × g. The cell pellet was fi xed for 
1 h at 4°C with 70% ethanol, washed with PBS, and treated for 1 
hour with 100 μg/ml of PI and 100 μg/ml RNase. DNA content was 
assessed by using an Epics Coulter XL fl owcytometer. Apoptosis 
was evaluated by Annexin V-FITC apoptosis detection kit (Sigma), 
which measures Annexin V binding to phosphatidylserine in 
conjunction with propidium iodide (PI) staining, according to the 
accompanying procedure.
3.5 Western blot analysis
Western blot analysis on whole-cell lysates was conducted. Cells 
were collected and washed with PBS before being lysed in Laemmli 
buffer. To detect phosphorylated proteins, cells were resuspended 
in lysis buffer (0,1% NaN3, 1 mM CaCl2, 1 mM MgCl2, 150 mM 
NaCl, 0.5 μM aprotinin, 4 μM leupeptin, 2 mM PMSF, 10 mM 
NaF, 10 mM iodoacetamide, 1 mM Na3VO4, 1% Triton-X 100 
in PBS) and kept for 30 min on ice. Where needed, nuclei were 
isolated (Foisy S et al., 1997) and lysed in Laemmli buffer. Equal 
amounts of proteins, as determined by RC-DC Protein Assay 
(Bio-Rad, Hercules, CA, USA), were resolved by 4–20% Bio-
Rad TGX gels and electroblotted to an Amersham Hybond PVDF 
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membrane (GE Healthcare, Milan, Italy).The blots were probed 
with the following primary antibodies: cyclin A (1:1,000), cyclin 
E (1:1,000), cdk1 (1:1,000), p27 (1:50), Mcl-1 (1:200; all by Santa 
Cruz Biotechnology); cdk2 (1:1000; Biomol); PARP (1:1,000; 
Alexis Biochemicals, Enzo Life Sciences); active caspase 3 
(1:1000; AbCam); XIAP and IAP1 (1:500; R&D System); FLIP 
(1:500; Upstate Biotechnology); phospho-p38 (catalogue no. 
9211), total p38, phospho-ERK1/2 (catalogue no. 9101), total 
ERK1/2 (1:1000; Cell Signaling); LMP1 (1:7500; Pharmingen); 
BZLF1(1:100 Argene); BRLF1 (1:2000 Argene), BFRF1(1:1000) 
and BFLF2 (1:10), kindly provided by Dr. A. Farina, Dept. of 
Experimental Medicine, Univ. of Rome ‘‘Sapienza’’, Italy; BALF5 
(1: 40) was a kind gift of Dr. F.Graesser, GSF-Forschungszentrum, 
Munich, Germany; NF–kb RelA/p65 (1:1000) and NF–kBp50 
(1:3000) were purchased from Millipore; β-actin (1:1500 Sigma). 
Membranes were incubated with secondary antibodies conjugated 
to horseradish peroxidase (BioRad) and signals were visualized by 
ECL detection kit (Amersham).
3.6 Electrophoretic Mobility Shift Assay (EMSA)
To determine NF-kB and AP1 activation, an electrophoretic 
mobility shift assay (EMSA) was carried out. Whole cell extracts 
were obtained after lysis in a high salt extraction buffer (50 mM 
Tris-HCl pH 7.5, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Triton X100, 0.5% NP40, 10% glycerol, 2 mM DTT, 2 μM 
aprotinin, 2 μM leupeptin, 1 mM Na3VO4, 2 μM pepstatin, 1 mM 
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PMSF). 20 μg were incubated with 30 fmol of a DIG-labeled (DIG 
oligonucleotide 3’ end-labeling kit, Roche Applied Science) NF–
kB (Zabel et al., 1991) and AP-1 (Saatian et al., 2006) DNA probe, 
in a binding buffer (20 mM Tris-HCl pH 7.5, 2 mM EDTA, 10% 
glycerol) containing 1 μg BSA, 0.5 μg poly d(I-C), for 20 min at 
room temperature. Complexes were resolved by nondenaturing 4% 
polyacrylamide gel electrophoresis, transferred to nylon membrane 
and detected by chemiluminescence (DIG luminescent detection 
kit, Roche Applied Science). The specifi city of binding was also 
verifi ed by competition with the unlabeled oligonucleotides. For 
supershift assay, cell extracts were incubated with antibodies 
against either p50 or p65 of NF-kB (Santa Cruz Biotechnology) 
for 30 minutes at room temperature and then analyzed by EMSA. 
Quantitative evaluation of NF-kB complex formation was carried 
out by ImageJ Freeshare Software (http://rsbweb.nih.gov/ij).
3.7 Fluorescence microscopy
Cells incubated with resveratrol or with diluent for 24 hours were 
washed with PBS, spotted on slides, and fi xed with methanol for 
5 minutes at - 20°C. Fixed cells were incubated with p65 NF-
kB subunit antibodies (1:500; Santa Cruz Biotechnology) for 1 
hour at 37°C, rinsed in PBS, and then incubated with fl uorescein 
isothiocyanate– conjugated secondary antibodies for 30 minutes 
at room temperature. Subsequently, cells were rinsed and nuclei 
stained with 4’,6-diamidino-2-phenylindole (DAPI; 0.2 μg/mL) 
for 15 minutes. The coverslips were mounted with 0.1% (w/v) 
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p-phenylenediamine in 10% (v/v) PBS, 90% (v/v) glycerol, pH 
8 (18), and the specimens observed by immunofl uorescence 
microscopy using a LeicaDM4000 fl uorescence microscope 
equipped with an FX 340 digital camera.
3.8 LMP1 silencing and overexpression
To obtain LMP1 downregulation, we used a human H1 RNA 
polymerase III promoter–based short hairpin RNA (shRNA) 
vector, pSilencer 3.1-H1 hygro (Ambion), to express siRNA that 
targets the EBV LMP1 in Raji cells. The sense- and antisense-
strand oligonucleotides for LMP1 shRNA were..5’-gatccGGA
ATTTGCACGGACAGGCttcaagagaGCCTGTCCGTGCAAA
TTCCttttttttggaaa-3’ and..5’-agcttttccaaaaaaaaGGAATTTGCA
CGGACAGGCtctcttgaaGCCTGTCCGTGCAAATTCCg- 3’. A 
pSilencer hygro vector expressing a hairpin siRNA with limited 
homology to any known sequences in the human genome was 
used as a negative control (control siRNA). The constructs were 
prepared by ligating the annealed oligonucleotides into the BamH1 
and HindIII of pSilencer and the resulting vectors analyzed by 
DNA sequencing. A total of 1.5 x 107 cells were electroporated 
with 30 μg of siRNA expression vectors at 975 μF, 260 V, using a 
Gene Pulser II system (Bio-Rad). To select clones, electroporated 
cells were grown in medium containing 100 μg/mL hygromycin 
(Sigma). After 3 weeks, resistant clones were grown up and tested 
for LMP1 protein expression. Transient expression of siLMP1 in 
LCLs was obtained by electroporation with the specifi c siRNA and 
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the control plasmid according to the conditions used for Raji cells. 
To enforce transient LMP1 expression, 1.5 x 107 EBV (-) Akata 
2A8 cells were electroporated (960 μF, 230 V) with 10 μg of LMP1 
expression vector pSG5-LMP1 (a kind gift of Dr Martin Rowe, 
Birmingham University Medical School, United Kingdom) or of 
the corresponding control vector pSG5.
3.9 Semiquantitative RT-PCR assay
Total RNA was extracted from cells by NucleoSpin RNAII columns 
and treated with DNase I (Macherey–Nagel, Duren, Germany). A 
total of 3 μg of the RNA was subjected to MMLV reverse transcriptase 
(Invitrogen) with 2.5 μM oligo(dT) primers (Sigma) in a 50 l 
reaction mixture according to the manufacturers’ protocols. 3 μl of 
RT products were analyzed undiluted or 1/10 and 1/20 diluted, by 
conventional PCR. As controls, PCR of RNA samples not subjected 
to RT and of RT products in the absence of primers, were used. 
Amplifi cations (25 cycles) were carried out with the following 
primers: BZLF1-F, 5’agaagcacctcaacctggagacaa; BZLF1-R, 
5’cagcgattctggctgttgtggttt; BRLF1-F, 5’tcactacacaaacagacgcagcca; 
BRLF1- R, 5’aatctccacactcccggctgtaaa; BALF5-F, 
5’cggaagccctctggacttc; BALF5-R, 5’ccctgtttatccgatggaatg; 
BHRF1-F, 5’gtcaaggtttcgtctgtgtg; BHRF1-R, 5’ttctcttgctgctagctcca; 
and GAPDH-F, 5’ttcgacagtcagccgcatcttctt; GAPDH-R, 
5’gcccaatacgaccaaatccgttga. Amplifi cation products were resolved 
on 1.5% agarose gels and stained by GelRed (Biotium).
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3.10 Real time PCR
Akata cells were treated for 24 h with IgG in the absence or in 
the presence of RV at 10, 20 and 40 μM. Cells were collected by 
centrifugation for 5 min at 300xg and culture supernatant used to 
determine EBV DNA copies by Real-Time PCR. The assay was 
performed essentially as described (Gaeta et al., 2009). Briefl y, 
extracted DNA was analyzed by a commercially available 
kit (Nanogen Advanced Diagnostics S.r.l.) based on TaqMan 
technology. A reporter dye 6-carboxyfl uorescein (FAM)-labeled 
probe for the viral EBNA1 gene was used for PCR reactions. 
Dilutions of plasmid carrying the specifi c viral gene were used 
to construct the reference curve and quantify viral DNA in the 
samples. PCR reactions were carried out with ABI PRISM 7000 
(Applied Biosystem, USA) according to the manufacturer’s 
protocol. Computer software quantifi ed the viral DNA load referred 
to the sample extracted volume.
3.11 Production of reactive oxygen species (ROS)
Akata cells were treated with anti-human IgG in the absence or in the 
presence of 10, 20 or 40 μM RV. Aliquots (2.5 x 105cells), incubated 
for the last 15 min with 40 μM 5,6-carbossy-2’,7’-diclorohydro 
fl uoresceine diacetate (DCFH-DA, Molecular Probes, Eugene, OR, 
USA) were collected at 30, 60 and 120 min. ROS production was 
analyzed by measuring the oxidized fl uorescent derivative DCF 
with a fl ow-cytometer (excitation: 488 nm, emission: 530 nm). 
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The levels of ROS detected in H2O2 treated cells have been used as 
positive controls.
3.12 Statistical analysis
Statistical analysis was carried out using the ANOVA followed by 
post hoc tests (Bonferroni/Dunn). The level of signifi cance was set 
at P < 0.05.
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4. Results
4.1 Resveratrol inhibits proliferation of EBV-positive BL cells
As we aimed to determine whether EBV gene expression played 
a role on the susceptibility of BL cells to resveratrol, we tested 
2 EBV(-) BL cell lines (2A8 and Ramos) and 3 EBV(+) BL cell 
lines, the latter expressing different patterns of EBV latency genes. 
In particular, Raji cells show a latency III phenotype; Jijoye M13, 
a subline of Jijoye cells classifi ed as group II like (Minarovits J. 
et al. 1991), express EBNA1 and LMP2A, whereas Akata cells 
display a latency I program. The cell lines, exposed to resveratrol 
concentrations increasing from 20 to 300 μmol/L for various periods 
of time, showed different degrees of sensitivity to the polyphenol. 
Figure 4 shows that the growth of each cell line was inhibited by 
resveratrol in a concentration- and time-dependent manner. The 
concentrations reducing cell proliferation by 50% at 48 hours 
were of about 300 μmol/L for Raji, 130 μmol/L for Jijoye M13 
cells, and 40 μmol/L for Akata and EBV(-) BL cells. The values 
determined for latency III and latency II cells were signifi cantly 
different between each other and with respect to latency I and EBV 
(-) cells (P < 0.05). Altogether, resveratrol cytotoxicity for EBV(-) 
and Akata cells was approximately 3- and 7-fold greater than that 
observed for Jijoye and Raji cells, respectively.
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Figure 4. 
Resveratrol-induced inhibition of BL cell proliferation. Cells were incubated with 
resveratrol at the concentrations indicated. After 24, 48, and 72 hours, cell counts 
were assessed by Trypan blue staining.
Percentage of proliferation was determined as proliferation of treated cells  x 100/
proliferation of control cells treated with the diluent. Each point represents the 
mean  ± SD of 3 similar experiments.
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4.2 Resveratrol induces cell-cycle arrest and apoptosis of 
EBV-infected BL cells
To investigate the antiproliferative effect of resveratrol on BL cells, 
we analyzed the cell-cycle distribution after incubation with the 
polyphenol. To compare the different cell lines, all the following 
experiments were carried out by exposing each cell line to the 
resveratrol concentration reducing cell proliferation by 50% at 48 
hours, as previously determined. Cells were harvested at 12 and 
24 hours, and the DNA content was determined by PI staining and 
fl owcytometric analysis. The bar graph in Figure 5A shows that 12-
hour treatment with resveratrol increased signifi cantly (P < 0.01) 
the percentage of cells in the G1 phase with a reduction of cells in 
S and G2–M phases. After 24-hour incubation, the G1 population 
further increased in Raji and Jijoye M13 cells whereas decreased 
in Akata cells, 2A8, and Ramos cells. In the latter (latency I and 
EBV(-) Burkitt’s lymphoma), the proportion of cells in the sub G0–
G1 phase, representing apoptotic events, augmented after 24-hour 
incubation (data not shown), suggesting a relation between cell-
cycle arrest and apoptosis. Therefore, we evaluated apoptosis in 
cells incubated with resveratrol for 12 and 24 hours, after staining 
with Annexin V and PI. Annexin V binding to phosphatidylserine, 
on the outer side of the cell membrane, characterizes the cells 
entering apoptosis, whereas cells double stained by Annexin V 
and PI represent the fraction of late apoptotic/ necrotic cells. As it 
appears from Figure 5B, the ratio between Annexin V and Annexin 
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V/PI-positive cells appeared to be dramatically different among 
the cell lines. In fact, after 24-hour exposure to resveratrol, the 
percentages of early apoptotic cells in Raji and Jijoye were about 
30% and 55% whereas the fractions of late apoptotic/ necrotic cells 
were about 8% and 12%, respectively. In addition, the percentage 
of Annexin V–positive cells in Jijoye M13 was signifi cantly higher 
than that measured in Raji (P < 0.0001). Conversely, in Akata 
cells as well as in 2A8 and Ramos cells, at both time points, the 
percentages of cells double stained by Annexin V and PI were 
larger than those of cells stained only by Annexin V. In particular, in 
EBV(-) 2A8 and Ramos, Annexin V/PI-positive cells reached about 
30% whereas single stained cells at 24 hours were about 12% and 
22%, respectively. In Akata, the fraction of double-positive cells 
was lower than those measured for EBV(-) cell lines but still higher 
than that of cells stained only by Annexin V. Taken together, these 
data seemed to indicate that EBV(-) BL cells and latency I Akata 
were more prone to resveratrol-induced apoptosis than latency II 
and latency III cell lines. Western blot analysis of PARP processing 
confi rmed that resveratrol differentially induced apoptosis in BL 
cells. As illustrated in Figure 5C, after 12-hour incubation, the 85-
kDa cleavage product of PARP appeared in latency I Akata and 
EBV(-) cell lines and further increased after 24 hours. In contrast, 
PARP apoptotic form was detectable in Jijoye M13 cells after 24-
hour exposure to resveratrol and in Raji cells only after 48 hours 
(data not shown), indicating that latency III BL cells were more 
resistant to resveratrol induced apoptosis than the other cell lines. 
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To investigate the apoptotic pathway, we analyzed the activation of 
effector caspase 3 by measuring the levels of the 17-kDa cleaved 
form. Data reported in Figure 5C showed higher levels of the 
biologically active caspase 3 along with increased amounts of the 
processed PARP, thus indicating that resveratrol induces apoptosis 
by the caspase-dependent pathway.
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Figure 5. 
Resveratrol (RV) induces cell-cycle arrest in G1 phase and apoptosis of BL cells. 
Each cell line was cultured with the resveratrol concentration reducing proliferation 
by 50% at 48 hours or with the diluent for 12 and 24 hours. A, fi xed cells were 
stained with PI and analyzed by fl ow cytometry. The percentages of cells in 
G1 (black bars), S (white bars) or G2–M phase (hatched bars) are shown. B, 
evaluation of apoptosis by FACS analysis after Annexin V and PI double staining.
Annexin V–positive cells (empty columns) and Annexin V/PI-stained cells (black 
columns), mean values  ± SD. *, P < 0.01 or **, P < 0.001 vs. Annexin V/PI. 
C, detection of PARP cleavage and active caspase 3. At the indicated times, 
cell lysates were prepared and analyzed by Western blots. -Actin was used as 
the internal marker. The data are representative of those obtained in at least 3 
independent experiments with similar results.
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4.3 Modulation of cell-cycle and apoptosis-associated 
proteins by resveratrol
To clarify the molecular mechanism of resveratrol-induced cell-
cycle arrest in G1 phase and the subsequent apoptosis, we examined 
by Western blot analysis the expression of several cell-cycle and 
apoptosis-related proteins (Fig. 6). Exposure to resveratrol increased 
the expression of the cdk inhibitor p27 and that of cyclin E in all 
cell lines; in contrast, cyclin A, cdk1, and cdk2 were downregulated 
in Raji and Jijoye M13 cells but did not vary signifi cantly in Akata 
and in the EBV(-) cell lines (Fig. 6A). Because S-phase cdk1/2 and 
cyclin A are essential for DNA synthesis, their decrement along with 
the increment of cdk inhibitor p27 indicate that resveratrol blocks 
specifi c cell-cycle–associated activity involved in the progression 
from G1 to S-phase. Moreover, the levels of the c-myc oncogene 
were strongly downregulated in Raji and Jijoye M13 cells and a 
signifi cant decrement was detected in Akata as well as in 2A8 and 
Ramos cells. The levels of expression of the antiapoptotic proteins 
IAP1, FLIP, and XIAP appeared to diminish in all cell lines, whereas 
Mcl-1 levels were reduced by 80% in Raji and 40% in Jijoye M13 
but only slightly in the other cell lines (Fig. 6B). Conversely, the 
Bcl-2 protein, whose gene is deleted in Ramos, was overexpressed 
in the other cell lines; furthermore, the tumor suppressor p53 gene, 
deleted in Akata, was upregulated in Raji, Jijoye M13, and Ramos 
cells (Fig. 7).
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Figure 6. 
Western blot analysis of cell cycle (A) and apoptosis (B) regulatory proteins 
following resveratrol treatment of BL cells. At the indicated times (hours), cell 
lysates were analyzed by 12% SDS-PAGE followed by immunoblot analysis. 
Specifi c signals were visualized and quantifi ed as described in Materials and 
Methods. A representative result of 3 independent experiments is shown. -Actin 
was used as the internal marker.
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Figure 7. 
Western blot analysis of p53 protein following resveratrol treatment of BL cells.  At 
the indicated times (hours), cell lysates were analyzed by SDS-PAGE followed by 
immunoblot analysis. Specifi c signals were visualized and quantifi ed as described 
in Methods. A representative result of three independent experiments is shown. 
β-actin was used as the internal marker.
4.4 Resveratrol activates p38 and inhibits ERK1/2 MAPK 
pathways
It has been reported that p38 MAPK and ERK signaling pathways 
may be important in determining cell proliferation or apoptosis. To 
investigate whether resveratrol treatment of BL cell lines affected 
MAPK pathways, we incubated EBV(+) and EBV(-) BL cells with 
the polyphenol for different periods of time and analyzed the cell 
lysates by Western blotting with phospho-specifi c antibodies (Fig. 
8). For each cell line, a positive control for MAPK activation pathway 
was obtained by exposing the cells to 12-O-tetradecanoylphorbol- 
l3-acetate (TPA) for 1 hour. Activation of p38 in Akata and Ramos 
cells was detected 3 hours after the addition of resveratrol, as the 
signal identifying phospho-p38 elevated to about 4- and 5-fold, 
respectively, with respect to that at time 0. A similar strong activation 
of p38 MAPK was observed for Raji and Jijoye M13 after 6 hours of 
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incubation with resveratrol. In contrast, the signals corresponding 
to phospho-ERK1/2, highly represented in untreated cells, rapidly 
disappeared following the addition of resveratrol, indicating that 
this pathway was dramatically inhibited by exposure of the cells to 
the polyphenol. Unexpectedly, both MAPK signaling pathways did 
not appear to be modulated by resveratrol in 2A8 cells, although 
they were both activated by TPA treatment. In addition, the analysis 
of the phosphorylation pathways of c-jun-NH2-kinase and protein 
kinase C did not reveal signifi cant variations in all BL cell lines 
exposed to resveratrol (data not shown).
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Figure 8. 
Western blot analysis of phosphorylation of p38 and ERK1/2 MAPK in resveratrol-
treated BL cells. At the indicated times (hours), cell lysates were prepared and the 
phosphorylation pattern of p38 and ERK was evaluated by Western blot analysis 
with the specifi c antibodies for each protein and its phosphorylated (p-) form; C+, 
TPA-treated cells as the positive control. Specifi c signals were visualized and 
quantifi ed as described in Materials and Methods.
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4.5 Resveratrol inhibition of NF-kB activity in BL cells
In BL tumor cells, c-myc overexpression is linked to chromosomal 
translocation in one of the Ig gene loci; it has been shown that NF-
kB activity is required for c-myc expression and constitutive NF-
kB DNA-binding activity in different types of B-cell malignancies, 
including Burkitt’s lymphoma, has been reported. To investigate 
the effect ofresveratrol on NF-kB activity in BL cells, EBV(+) and 
EBV (-) cell lines were treated with resveratrol or control diluent 
for up to 9 hours. After different periods of incubation, whole-cell 
extracts were used to measure NF-kB activity by EMSA. Figure 
9A shows that Raji and Akata cells displayed high constitutive NF-
kB DNA-binding activity. Resveratrol caused a marked inhibition 
of NF-kB activity in Akata cells already after 1 hour of treatment. 
In Jijoye M13, 2A8, and Ramos cells, after a rapid and transient 
increment, NF-kB activity decreased under control levels. In con-
trast, exposure of Raji cells to resveratrol did not signifi cantly alter 
NF-kB DNA-binding activity during the fi rst 9 hours of treatment. 
To confi rm that the retarded band visualized by EMSA was indeed 
NF-kB, cell extracts were incubated with antibodies to either p50 
or p65 and then analyzed by EMSA. Antibodies to either subunit 
of NF-kB shifted the band to higher molecular weight, suggesting 
that the active complex consisted of p50 and p65 subunits (Fig. 10). 
The effect of resveratrol on NF-kB activity seemed to be specifi c 
for this transcription factor because EMSA carried out to measure 
AP1 activity in parallel samples did not reveal a signifi cant decre-
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ment in EBV-positive cell lines and variable levels were detected in 
EBV(-) cells (Fig. 11). NF-kB–binding activity decreased, howe-
ver, in all cell lines treated for prolonged time with resveratrol (data 
not shown). Immunofl uorescence studies and Western blot analysis 
conducted on Raji cells exposed to the polyphenol for 24 hours 
showed a dramatic decrement of the p65 subunit (Fig. 9B and C). 
In particular, the fl uorescent signal decorating the nucleus and the 
cytoplasm of untreated cells in bright patches appeared weak and 
mainly localized to the cytoplasm in resveratrol-treated cells.
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Figure 9. 
NF-kB activity in resveratrol-treated BL cells. A, at the indicated times (hours), 
whole-cell extracts were incubated with a consensus NF-kB–binding site 
oligonucleotide to evaluate NF-kB activity by EMSA (see Materials and Methods). 
The signals, quantifi ed by densitometry, are expressed as fold induction of time 
0. The data shown are representative of 3 independent experiments with similar 
results. B, Raji cells untreated or treated with resveratrol for the times indicated 
were analyzed with RelA/p65 antibodies by indirect immunofl uorescence; DNA 
was visualized with DAPI, and the merge images are displayed; scale bar, 20 
μm. C, 50 μg of nuclear proteins from Raji cells untreated (0) or treated with 
resveratrol for 12 and 24 hours were subjected to SDS-PAGE and Western blot 
analysis with RelA/p65 antibodies as described (see Materials and Methods).
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Figure 10. 
Supershift assay . The cell extracts from control cells and cells treated for three 
hours with RV, were incubated with anti-p65 or anti-p50 antibodies and analyzed 
by EMSA. Lane 1, without cell extract; Lane 2 and 6, kB probe alone; Lane 3 and 
7, with p65 antibody; Lane 4 and 8 with p50 antibody; Lane 5, unlabeled probe.
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Figure 11. 
AP1 activity in resveratrol-treated BL cells. (a) At the indicated times (hours), whole-
cell extracts were incubated with a consensus AP1 binding site oligonucleotide to 
evaluate AP1 activity by EMSA (see Methods).
4.6 LMP1 expression modulates the sensitivity of BL cells to 
resveratrol
Because Raji cells seemed to be more protected from resveratrol-
mediated apoptosis, we looked for EBV genes expressed in the 
latency III program that would confer additional survival advantage 
against the effects of the polyphenol. LMP1 is the principal EBV 
oncogene with the potential to antagonize apoptosis as well as 
to promote cellular survival and proliferation (Li HP et al.2003; 
Dirmeier U et al. 2005; Soni V et al.2007). We therefore set to 
investigate the effects of resveratrol after silencing LMP1 expression 
in Raji cells. Raji 5E, a clone selected after transfection of Raji 
cells with a construct expressing LMP1 siRNA, and Raji control 
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transfected with a control plasmid were exposed to resveratrol or 
to the diluent for 24 hours and viable cells determined by Trypan 
blue staining. Figure 12A shows that in Raji 5E, cell proliferation 
was reduced by about 40% as compared with that measured in 
the control. This result clearly indicated that inhibition of LMP1 
expression in clone 5E, as confi rmed by Western blot analysis 
(Fig. 12B), dramatically increased the sensitivity of latency III 
Raji cells to resveratrol. The analysis of NF-kB DNA-binding 
activity by EMSA in Raji control and Raji 5E revealed in the latter 
a strong reduction of the band corresponding to the DNA–protein 
complex, indicating that inhibition of LMP1 expression in Raji 
5E resulted in a lower stimulation of the transcription factor (Fig. 
12C). To further investigate links between LMP1 expression and 
sensitivity of BL cells to resveratrol, we transfected EBV (-) 2A8 
cells with the LMP1 plasmid or the control vector; 24 hours later, 
cells were exposed to either resveratrol or the diluent and viable 
cells determined by Trypan blue staining after a further 24-hour 
period. Figure 12D shows that 24 hours after transfection, LMP1 
plasmid had effi ciently promoted the expression of the protein. As 
expected, cell proliferation of EBV(-) 2A8 cells transfected with 
the control plasmid was strongly reduced by exposure to resveratrol 
as compared with control cells treated with the diluent. In contrast, 
proliferation of 2A8 cells expressing the viral oncogene and treated 
with resveratrol was similar to that observed for the control cells 
(Fig. 12E). These results clearly indicate that LMP1 expression 
increases the resistance of BL cells to the polyphenol.
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4.7 LMP1 downregulation increases the antiproliferative 
effect of resveratrol on LCLs
To validate the cooperative effects of LMP1 suppression and 
resveratrol treatment in inhibiting cell proliferation of EBV-
infected latency III cells, we exposed to the polyphenol 2 LCLs 
silenced for LMP1. To this end, cells were fi rst electroporated 
with LMP1 siRNA or control plasmid and 24 hours later treated 
with or without resveratrol for the next 24 hours at concentration 
previously found to effectively inhibit LCLs proliferation (Fig. 13). 
Cell counts were determined by Trypan blue exclusion assay, and 
apoptosis levels were assessed by detection of PARP cleavage on 
Western blots. Figure 14A shows that electroporation of LCL1260 
with control plasmid (siRNA C) did not affect LMP1 expression; 
Figure 12. 
Infl uence of LMP1 expression on Burkitt’s lymphoma sensitivity to resveratrol 
(RV). A, Raji cells expressing control siRNA (control) or siRNAs targeting LMP1 
(5E) were treated with resveratrol (black columns) or with diluent (empty columns) 
for 24 hours and cell viability was measured by Trypan blue staining; values are 
means ± SD of 3 different experiments and are presented as the percentage of 
control; B, LMP1 protein levels in Raji cells expressing control siRNA (control) 
or siRNAs targeting LMP1 (5E) were assessed by Western blot analysis; -actin 
was used as a loading control. C, NF-kB DNA-binding activity in Raji control and 
Raji 5E was detected by EMSA (see Materials and Methods).
D, 2A8 cells were electroporated with either pSG5 or pSG5-LMP1 plasmid and 
24 hours later analyzed by Western blotting for LMP1 expression. E, 2A8 cells 
treated as in (D) were exposed to resveratrol (black columns) or the diluent 
(empty columns) for 24 hours and cell viability was measured by Trypan blue 
staining; values are means ± SD of 3 different experiments and are presented as 
the percentage of control.
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in contrast, transfection of the cells with LMP1siRNA decreased 
LMP1 levels by about 30% to 40% at 24 hours and by about 80% 
at 48 hours. Following 24-hour exposure of the cells to 130 or 220 
μmol/L resveratrol, proliferation of LCLs with control siRNA was 
inhibited by 45% and 55%, respectively (Fig. 14B). However, LMP1 
downregulation by siRNA dramatically reduced the viability of the 
cells treated with the polyphenol and strongly induced apoptosis as 
revealed by the high levels of PARP cleavage product (Fig. 14C). 
Similar results were obtained with LCL1087 (data not shown). 
Altogether, our data indicated that LCLs expressing lower levels of 
LMP1 were more sensitive to resveratrol induced apoptosis.
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Figure 13. 
Resveratrol-induced inhibition of LCLs proliferation. Cells were incubated with 
RV at the concentrations indicated. After 24, 48 and 72 hours, cell counts were 
assessed by trypan blue staining and the values expressed as percentage of 
control cells treated with the diluent. Each point represents the mean ± SD of 
three similar experiments.
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Figure 14. 
Downregulation of LMP1 expression increases resveratrol (RV)- induced cell 
growth inhibition and apoptosis of LCLs. A, cells were electroporated with control 
siRNA (siRNA C) or siRNAs targeting LMP1 (siRNA LMP1) and, at the time 
indicated, LMP1 protein levels analyzed by Western blotting; B, LCLs treated as 
in (A) and incubated for 24 hours were exposed to 130 μmol/L (pointed columns), 
220 μmol/L (dashed columns) resveratrol, or to diluent (empty columns) for 24 
hours. Cell counts were determined by Trypan blue staining, and the values 
expressed as the percentage of control cells treated with the diluent. Each value 
represents the mean ± SD of 3 similar experiments. C, samples of cells treated 
as in (B) were collected after electroporation (0), 24 hours later (24), and following 
exposure for 24 hours to either resveratrol or the diluent (+24). A total of 20 μg of 
cell lysates was resolved on 8% to 16% acrylamide gel and analyzed by Western 
blotting with PARP antibodies.
Data shown are representative of 3 independent experiments.
4.8 Evaluation of the cytotoxicity of resveratrol on Akata cells 
upon EBV lytic cycle induction
The concentrations of the polyphenol causing a 50% reduction in 
the proliferation of Raji and Akata cells at 48 h, equal to 300 and 40 
μM, respectively, were chosen as the highest values of a range used 
to examine the effects of RV on EBV replicative cycle in the two cell 
lines. EBV lytic cycle was induced in Raji cells by electroporation 
of the plasmid expressing the immediate early gene BZLF1 and in 
Akata cells by IgG cross-linking. In the latter cellular system for 
EBV replication, we evaluated a putative cytotoxic effect of RV by 
Trypan blue exclusion assay and by cytofl uorimetric determination 
of apoptotic/necrotic cells after FITC-Annexin V and propidium 
iodide (PI) staining. The data reported in Figure 15 show that cell 
counts, determined after 24 h incubation of Akata cells with 40 
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μM RV, were reduced by about 40% with respect to control cells 
incubated with IgG in the absence of the compound, while only a 
10–20% decrement was measured after exposure of the cells to RV 
concentrations of 10 and 20 μM respectively. In agreement with 
these data, in the presence of 40 μM RV, the percentage of the cell 
population stained by Annexin V was about 30% higher than that 
measured in the absence of the polyphenol, while an increment of 
10–20% was detected with RV concentrations of 10 and 20 μM 
(Fig. 15B). Interestingly, the percentages of necrotic cells (stained 
with PI), and those of late apoptotic cells (Annexin V/PI-positive) 
detected after 24 h incubation, were substantially low and not 
signifi cantly affected by the treatment with RV. These results 
clearly show that at the concentrations used for our experiments, 
RV inhibits the proliferation of Akata cells without increasing cell 
death.
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Figure 15. 
Antiproliferative effect of RV on Akata cells upon EBV lytic cycle induction.
IgG cross-linked Akata cells were treated with RV at the concentrations indicated 
for 24 h. (A) cell counts were assessed by Trypan blue staining. The values 
represent the mean ±SD of three similar experiments. (B) Samples of cells treated 
as in (A) were subjected to Annexin V (AnnV) and PI staining and analyzed by 
fl owcytometry as described in the Methods. The table reports the results of a 
representative experiment as percentages of apoptotic cells (AnnV-positive), 
necrotic cells (PI) and late apoptotic cells (AnnV and PI positive).
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4.9 Down-regulation of EBV lytic antigens expression by 
resveratrol
To examine the effects of RV on EBV lytic antigens expression, 
Raji cells were treated with concentrations of the polyphenol 
varying from 50 to 300 μM for 24 h, while Akata cells with 
concentrations varying from 10 to 40 μM for six hours. Cell lysates 
were analyzed by Western blot with antibodies specifi c for the two 
EBV immediate early (IE) antigens BZLF1 and BRLF1 and for the 
early (E) proteins, BFRF1, BFLF2 and the viral DNA polymerase 
BALF5. Fig. 16 shows that 24 h after electroporation of Raji cells 
with the BZLF1 plasmid, EBV immediate early and early antigens 
were effi ciently expressed. In contrast, viral lytic antigens were 
not expressed in Raji cells electroporated with the CMV vector 
(data not shown).When 300 μM RV was added to the cell culture, 
BZLF1 and BRLF1 signals, as well as those representing BFRF1, 
BFLF2 and BALF5 antigens, were barely detectable. Moreover, a 
dose-dependent effect on the expression of EBV early antigens and 
BRLF1 was observed with lower concentrations of the polyphenol. 
In contrast, concentrations of RV lower than 300 μM increased 
BZLF1 levels suggesting a stimulatory effect on the expression of 
the BZLF1 plasmid. The results obtained in Akata cells show that 
EBV IE and E genes were highly expressed after 6 h incubation 
with IgG. The addition of RV to the cell cultures inhibited the 
expression of all EBV lytic antigens in a concentration-dependent 
manner so that at 40 μM, the reduction of protein levels, measured 
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by densitometric evaluation of the specifi c signals, was close to 
90%. Because RV similarly inhibited EBV lytic antigens expression 
in Raji and Akata cells, the effects of the polyphenol appeared to 
be independent of the method used to trigger viral reactivation. 
Therefore, further experiments have been performed on Akata cells 
that allow full completion of EBV lytic cycle.
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Figure 16. 
Expression of EBV lytic antigens in Raji and Akata RV-treated cells. Raji and 
Akata cells treated as described in the Methods to induce EBV lytic cycle, were 
incubated in the absence or in the presence of RV at the indicated concentrations 
for 24 and 6 h, respectively. Cell lysates (40 μg) were resolved by SDS–PAGE, 
blotted on membrane and probed with antibodies for EBV antigens. Specifi c 
signals were visualized by ECL. -Actin was used as the internal marker. The 
data are representative of those obtained in at least 3 independent experiments 
with similar results.
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4.10 Modulation of EBV lytic gene expression occurs at the 
post-transcriptional level
To gain insights into the regulation of EBV lytic gene expression 
by RV, we measured mRNA levels of the viral IE genes in 
untreated and RV-treated cells by semi-quantitative RT-PCR. As 
shown in Fig. 17A, even at the highest concentration, RV did not 
signifi cantly affect the transcription of BZLF1 and BRLF1 genes. 
Similar results were obtained when the levels of EBV early genes 
BHRF1 and BALF5 were evaluated (data not shown). Therefore, 
the down-regulation exerted by the polyphenol on EBV lytic gene 
expression appeared to occur at the post-transcriptional level. To 
investigate whether inhibition of EBV mRNAs translation could 
account for the decrement of the viral lytic antigens observed after 
RV administration, EBV lytic cycle was induced in the presence 
of either the protein synthesis inhibitor cycloheximide (CHX) or 
RV, each added at time zero (together with the IgG), 2 or 4 h later. 
The levels of EBV lytic antigens were measured byWestern blot 
of cells harvested at 8 h. As shown in Fig. 17B, inclusion of CHX 
or RV for the 8 h duration of the experiment strongly inhibited 
the synthesis of BZLF1, BRLF1 and BALF5 induced by IgG 
(lanes 0–8). The addition of the two compounds 2 and 4 h after 
EBV induction, completely abolished their inhibitory effect on 
EBV lytic antigens expression. In fact, similar levels of the viral 
products were detected upon addition of either CHX or RV at 2 
or 4 h after EBV induction. All together these results suggest that 
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down-regulation of EBV lytic antigens expression observed in the 
cells simultaneously exposed to IgG and RV, might involve a block 
in the synthesis of protein factors required in the early phases of 
EBV productive cycle. We also measured the abundance of BZLF1 
mRNA by RT-PCR in the samples harvested at 8 h. Fig. 17C shows 
that the mRNA levels were similar in the cells treated with either 
RV or CHX, implying that the expression of BZLF1 mRNA was 
independent of new protein synthesis.
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Figure 17. 
EBV lytic genes expression in RV-treated cells. (A) EBV lytic cycle was induced 
in Akata cells in the absence or in the presence of 10, 20 or 40 μM RV for 6 h. 
Total RNA was purifi ed and subjected to reverse transcription as described in the 
Methods. Undiluted and diluted cDNA were analyzed by PCR with the specifi c 
primers for BZLF1 and BRLF1 genes. GAPDH amplifi cation was used to verify 
equal amounts of total RNA. (B) Akata cells treated with IgG were harvested at 0, 
2, 4, and 8 h. CHX or 40 μM RV were added with the inducing agent (lane 0–8) 
or at 2 h (lane 2–8) and at 4 h (lane 4–8) after EBV lytic activation. Cell lysates 
were prepared from all treated cells 8 h after starting the experiment. Expression 
of EBV antigens was analyzed by immunoblotting. -actin was used as loading 
control. (C) Total RNA was extracted from Akata cells treated as in (B) and RT-
PCR was performed as described in the Methods. Representative results of 3 
independent experiments are shown.
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4.11 Inhibition of viral particles production by resveratrol
The strong down-regulation of EBV lytic gene expression observed 
after exposure of the cells to RV led us to investigate the effects of 
the polyphenol on EBV replication. To this end, EBV copies were 
measured in the medium of Akata cells exposed for 24 h to IgG 
with or without different RV concentrations. The results, illustrated 
in Fig. 18A, show that EBV particles production was modulated by 
RV in a dose-dependent manner. In the presence of 10 μM RV, EBV 
copies released in the medium were about 65% of those measured 
in the absence of the polyphenol. A progressive decrement of EBV 
particles was observed when the induction of the EBV lytic cycle 
was carried out in the presence of either 20 or 40 μM RV as the 
EBV copies measured under these conditions were about 45 and 
30% respectively, of those released in the absence of the compound.
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4.12 Resveratrol inhibition of EBV lytic cycle is associated 
with reduced ROS generation
It has been well established that many pharmacological actions of 
RV are due to its anti-infl ammatory and anti-oxidant properties. 
To clarify whether RV down-regulation of EBV lytic cycle was 
associated with a decrement of ROS, the cellular redox state 
was analyzed in RV-treated or untreated Akata cells after EBV 
activation. After 30, 60 and 120 min, cell samples were subjected 
to fl ow-cytometric analysis to quantify ROS levels by the ROS-
sensitive fl uorescent product DCF. We found that ROS markedly 
decreased in the cells exposed to RV during the induction of EBV 
lytic cycle (Fig. 18B). After 30 min, ROS levels measured in RV-
treated cells were about 45% of those measured in the absence of 
the polyphenol. In addition, the values obtained after 60 and 120 
min of incubation, were about 55 to 40% and 60 to 42% of the 
control, respectively, depending on RV concentrations and the time 
elapsed from EBV lytic cycle activation.
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Figure 18. 
(A) Inhibition of viral particles release from RV-treated cells. Akata cells were treated 
for 24 h with IgG in the absence or in the presence of RV at the concentrations 
reported. The culturing medium was collected and EBV DNA measured by real-
time PCR, as described in the Methods. The values in the bargraph are means ± 
SD of 3 different experiments and are presented as the percentage of control (in 
the absence of RV).*P < 0,001 or **P < 0,0001. (B) Inhibition of ROS production 
in RV-treated cells. Akata cells were exposed to IgG in the absence or in the 
presence of RV at 10, 20 or 40 μM. At the indicated times, samples were analyzed 
to determine ROS levels as described in the Methods; values in the bar-graph are 
means ± SD of 3 different experiments and are presented as the percentage of 
control (in the absence of RV).*P < 0.05 or **P < 0.01.
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4.13 Effects of resveratrol on EBV-mediated transcription 
factors activation
Since RV has been reported to inhibit the activity of several 
transcription factors, we measured NF–kB and AP-1 DNA binding 
capacity after activating EBV in Akata cells exposed or not to RV. 
As shown in Figure 19, within three hours following induction of 
EBV lytic cycle,NF–kB DNA-binding activity rapidly increased 
reaching a three fold higher level than that measured at time zero; 
there after it declined and by 6 h returned to the levels measured 
before EBV reactivation. Addition of RV during EBV induction 
rapidly inhibited the initial phase of NF–kB activation. In fact, 
the signals corresponding to the DNA–protein complexes were 
similarly high in untreated and RV-treated cells after one hour 
of treatment but had declined to base levels already after three 
hours exposure of the cells to the polyphenol. Similar results were 
obtained when cells extracts were assessed for AP-1 DNA binding 
activity, clearly indicating that RV treatment inhibited the boosted 
activity of transcription factors induced by EBV lytic switch. To 
assess whether the decrement of transcription factors activities 
could be ascribed to decreased amounts of the constituting subunits, 
the levels of p65 and p50 NF–kB components were measured by 
Western blot analysis in the cell extracts used for EMSA. The data 
illustrated in Figure 20 show that treatment of Akata cells with IgG 
in the absence or in the presence of 40 μM RV did not alter the 
levels of NF–kB protein components, indicating that the polyphenol 
mainly affected the binding activity of the transcription factor.
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Figure 19. 
NF–kB and AP-1 activities in RV-treated cells. Akata cells were exposed to IgG 
and 40 μM RV. At the times indicated, whole-cell extracts were obtained and 
equal amounts of proteins incubated with the NF–kB or AP-1 probe. Transcription 
factors activities were evaluated by EMSA (see Materials and Methods). The 
signals, quantifi ed by densitometry, are expressed as fold induction of time 0. The 
data shown are representative of 3 independent experiments with similar results.
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Figure 20. 
Evaluation of NF–kB subunits expression in RV-treated cells. 30 μg of cell lysates 
from Akata cells untreated (0) or IgG cross-linked and treated or not with 40 μM 
resveratrol for 3 and 9 hours, were subjected to SDS-PAGE and Western blot 
analysis with RelA/p65 and p50 antibodies as described (see Materials and 
Methods). β-Actin was used as the internal marker. The data are representative 
of those obtained in at least 3 independent experiments with similar results.
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5. Discussion
Three main patterns of differential EBV expression have been 
described in infected cells in lymphoproliferative disorders, as 
Latency I, II, or III. The prototypic malignancy with Latency 
I is Burkitt lymphoma, while Latency II is seen in Hodgkin 
lymphoma and Latency III in AIDS-related diffuse large B cell 
lymphoma (immunoblastic subtype) and post-transplantation 
lymphoproliferative disorders.
In terms of how to use this knowledge to develop new antivirals, 
it is evident that by inhibiting EBNA1, the only gene expressed in 
all phenotypes, it could be possible to diminish the EBV effects 
in the largest number of viral lymphomas. Moreover, because 
EBNA 1 protein is also involved in episome maintenance, it might 
be conceivable to eliminate the viral genomes from the lymphoma 
cells . However, although RNA interference to EBNA1 used in a 
Burkitt lymphoma line, decreased cell proliferation (Hong M et al. 
2006), dependency of infected tumor cells on EBNA1 is not very 
clear.
In fact, some Burkitt lymphomas were found to express a viral 
protein called BHRF1, which is a viral homolog of BCL2, an 
important antiapoptotic protein (Kelly GL et al., 2009). Moreover, 
one endemic Burkitt’s lymphoma case was found to be unusually 
heterogeneous and in early-passage cultures yielded clones that, 
besides c-myc translocation, differed in EBV status showing 
3 forms of restricted latency correlated with specifi c degree of 
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protection from apoptosis (Kelly GL et al., 2002, 2005, 2006). These 
fi ndings indicate that multiple viral genes can block apoptosis and 
different Burkitt’s lymphomas express different combinations of 
these antiapoptotic genes that contribute survival functions of these 
tumors in multiple ways. Therefore, inhibition of these proteins or 
of the signaling pathways they activate, could be useful to treat the 
lymphomas with type II and III latency where these viral products 
are expressed. These include Hodgkin’s lymphoma, post-transplant 
lymphoproliferative disorders, and a subset of AIDS related 
lymphomas.
A great variety of naturally occurring compounds have been 
shown to inhibit, delay, or reverse cellular events associated 
with carcinogenesis by acting on multiple targets and therefore 
representing a promising alternative or support to conventional 
therapies for the management of cancer (Benner SE, Hong WK 
1993). Among them, resveratrol is a dietary chemopreventive 
phytochemical that has gained considerable attention for its 
remarkable inhibitory effects on different stages of carcinogenesis 
(Jiang H et al., 1997).
The experiments carried out in 3 EBV-positive BL lines that express 
just EBNA1 as in Akata, a latency II-like pattern with the exception 
of LMP1 (EBNA1+/LMP2A+) as in Jijoye M13, and the latency III 
phenotype as in Raji, respectively, have allowed us to evaluate the 
antiproliferative effect of resveratrol on cells in which EBV infection 
was associated with a specifi c degree of protection from apoptosis. 
We found that resveratrol causes cell-cycle arrest and apoptosis of 
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EBV-infected BL cells independently of the latency program the 
virus established in the host cells. However, the effi cacy of the 
polyphenol seems to be inversely related to the restriction pattern 
of viral gene expression. Thus, latency I infection in Akata cells 
confers a small but signifi cant protective effect whereas latency 
II-like infection in JijoyeM13 and latency III in Raji cells, further 
broadening EBV latent genes expression pattern, progressively 
diminish the sensitivity of BL cells to resveratrol-induced 
apoptosis. The different susceptibility of BL cells to resveratrol is 
refl ected in the variable concentrations of the polyphenol necessary 
to reduce proliferation by 50%. Our results show that the growth 
inhibitory potential of resveratrol is mainly due to the induction 
of cell-cycle arrest and apoptosis because a signifi cant fraction of 
the cell population accumulated in the G1 phase of the cell cycle 
after exposure to the polyphenol. Cytofl uorimetric evaluation 
of Annexin V and Annexin V/PI-positive cells revealed that G1 
block triggered a high percentage of EBV(-) and latency I BL 
cells to rapidly proceed toward late apoptosis/necrosis, whereas 
the proportion of early apoptotic cells further increased in latency 
II-like and latency III BL cells during 24-hour treatment with the 
polyphenol. Resveratrol-induced cell-cycle arrest in G1 seemed to 
be associated with the modulation of cell-cycle regulatory proteins 
involved in the G1–S transition because a decreased expression of 
cyclin A, cdk1, and cdk2 as well as an up-regulation of cyclin E and 
the cdk inhibitor p27 were detected.
It has been shown that c-myc down-regulation is a critical molecular 
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event of resveratrol-mediated antiproliferative activity, closely 
associated with growth suppression, cell cycle arrest, and apoptosis 
(Zhang W et al., 2007; . Paul S et al., 2009). Our data indicate 
that resveratrol suppresses c-myc expression in all BL cell lines, 
regardless of EBV status. Because c-myc is the master transcription 
factor responsible for proliferation of BL cells, EBV (-) and latency 
I BL cell lines might be very sensitive to c-myc repression and cell-
cycle arrest and readily die by apoptosis or necrosis rather than 
sustaining a prolonged arrest of proliferation. Moreover, the higher 
protection of Raji and Jijoye M13 cells from apoptosis, despite the 
striking and rapid decrement of c-myc levels, seems most likely 
due to the expression profi le of EBV genes in these cell lines. With 
respect to Jijoye M13, protection from apoptosis has been previously 
reported in LMP2A-expressing cell lines (Fukuda M et al., 2005; 
Mancao C and Hammerschmidt W 2007). PARP cleavage and 
caspase 3 activation detected in all BL cells suggest that resveratrol 
may induce cell death, at least in part, through caspase-dependent 
pathway. We have found that resveratrol-induced apoptosis occurs 
in conjunction with down-regulation of the antiapoptotic proteins 
cIAP1, FLIP, and XIAP. Because these proteins inhibit caspase 
activity (Deveraux QL et al., 1998; Hideshima T et al., 2003; 
Mitsiades N et al., 2002), it is conceivable that resveratrol might 
induce apoptosis by down-regulating their expression. Our data 
concerning the analysis of cell cycle and apoptosis related factors in 
resveratrol-treated BL cells also showed that, overall, the variations 
of protein levels were much more pronounced in Raji and Jijoye 
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M13 cells than in Akata or EBV(-) cell lines. A likely explanation 
for the lower reactivity of the latter cell lines can be found in the 
rapid and massive cell death that follows resveratrol-induced block 
of cell-cycle progression. 
A great deal of experimental evidence has been provided for p38 
MAPK involvement in apoptosis triggered by a variety of agents, as 
well as in the regulation of cell cycle G1–S and G2–M checkpoints 
in response to cellular stress and DNA damage (Xia Z et al., 
1995; Thornton TM, Rincon M 2009). Although p38 MAPK is 
generally believed to be a kinase that mediates cell death, ERK1/2 
MAPK pathways have been shown to promote survival and cell 
growth (Meloche S, Pouyssegur J 2007). Our fi ndings indicating 
inhibition of ERK1/2 activity and the concomitant activation of 
p38 signaling cascade confi rm the opposite effects these kinases 
play in determining cell survival/death and may account for the 
observed antiproliferative activity of resveratrol on BL cells. 
It has been proposed that ERK1/2 kinases regulate G1 phase 
progression through various mechanisms including cyclin D1 
induction, enhanced c-myc protein stability, p27 down-regulation, 
and decreased expression of antiproliferative genes (Meloche S, 
Pouyssegur J 2007; Yamamoto T et al., 2006). Although cyclin 
D1 protein levels were barely detectable in resveratrol-treated BL 
cells, our results showing c-myc suppression and the increment of 
p27 protein levels suggest the involvement of ERK1/2 pathway in 
mediating resveratrol-induced cell-cycle arrest. 
NF-kB activation has been linked to several aspects of oncogenesis, 
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including the control of cell migration, cellcycle progression, and 
differentiation, as well as apoptosis (Karin M 2006). In general, 
NF-kB exerts an antiapoptotic activity by switching on genes that 
hamper the effects of proapoptotic stimuli, thereby suppressing cell 
death pathways. Genes whose activity is positively regulated by 
NF-kB include members of the Bcl-2 family, TRAF1/2, cIAP1/2, 
cFLIP, and XIAP (Karin M et al., 2002). BL cells often present 
aberrant NF-kB regulation and express constitutive high levels 
of NF-kB activity (Ni H et al., 2011, Piva R et al., 2005). Our 
data, indicating that resveratrol markedly inhibits NF-kB activity 
in EBV(-) 2A8 and Ramos, latency I (Akata), and latency II-like 
(Jijoye M13) BL cells, are in agreement with what previously 
reported on the inhibitory effect of the polyphenol on the activity of 
the transcription factor (Gupta SC et al., 2010) although, in latency 
III Raji cells expressing the EBV oncogene LMP1, suppression of 
NF-kB activity was observed only after prolonged treatment with 
the polyphenol. 
Among the BL cell lines examined in this study, only Raji expresses 
the EBV oncogene LMP1 because the Jijoye subline M13, deleted 
for EBNA2, lacks the viral latent membrane protein. LMP1, as 
the critical activator of NF-kB (Cahir McFarland ED et al., 1999, 
Wu L et al., 2006), is responsible for the dramatic differences in 
the growth pattern and phenotype of cells driven into proliferation 
by either c-myc or the EBV latency III program (Dirmeier U et 
al., 2005). We have found that LMP1 down-regulation decreases 
the protection of Raji cells to resveratrol-induced apoptosis and 
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conversely that LMP1 overexpression protects EBV(-) 2A8 cells 
from resveratrol treatment. Because of the LMP1 stimulatory effect 
on NF-kB, it is conceivable that LMP1 increases the resistance of 
latency III BL cells to resveratrol by transcription factor activation. 
All together, for what concerns EBV latent infection of B 
lymphocytes, our data show that in BL cells, induction of apoptosis 
mediated by resveratrol is clearly different between EBV(-) and 
EBV-infected cells that sustain a type I, II, or III latency program. 
These results suggest that the assessment of the different viral 
latency programs might have great impact for the treatment and 
sub-classifi cation of Burkitt’s lymphoma and other EBV-related 
malignancies.
In vivo, the activation of the lytic cycle, in a relatively small number 
of infected B cells leads to the production of viral particles that 
spread EBV infection. Lytic activation is also observed in acute 
infectious mononucleosis as well as in post-transplant lymphomas 
and lymphoproliferative diseases that occur in immunocompromized 
patients.
In these studies we found that resveratrol is able to inhibit EBV 
lytic cycle in Burkitt’s lymphoma cells when induced either by the 
ectopic expression of the immediate early gene BZLF1 as in Raji 
cells, or by activation of the B-cell receptor signaling pathway as in 
Akata cells. In the latter that support the complete replicative cycle, 
we showed that RV treatment reduced EBV particles production in 
a concentration dependent manner, without signifi cantly affecting 
cell viability. The data reported here, indicate that upon EBV lytic 
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cycle induction, RV antiproliferative effects during productive 
infection are even more pronounced since, in the two cell lines, 
the concentrations able to reduce by 50% the proliferation of 
EBV latently-infected cells at 48 h, caused similar decrements 
24 h after induction of EBV lytic cycle. However, despite the 
increment of early apoptic (AnnV-positive) cells with increasing 
RV concentrations, the percentages of late apoptotic and necrotic 
Akata cells did not represent any relevant value, indicating that cell 
viability was not affected even by the highest concentration of the 
drug. Moreover, because EBV induction blocks the cell cycle at 
G1/S (Wu et al., 2004), the effects of RV on EBV lytic cycle have 
to be considered independent of the arrest of cellular proliferation. 
We demonstrate that down-regulation of EBV genes expression by 
RV occurs without variation of the corresponding mRNA levels, 
indicating that the polyphenol acts at a post-transcriptional level. 
We also show that in the absence of signifi cant alterations in the 
amounts of the transcripts, the expression of EBV lytic products is 
largely suppressed when lytic cycle is carried out in the presence 
of either RV or CHX, and that the inhibitory effect of the two 
compounds is lost when they are added to the cells 2 or 4 h after 
IgG stimulation. This result, while strongly suggesting a similar 
mechanism for the two compounds, indicates that both exert their 
effects only in the very early phases of EBV induction. Because, at 
least CHX, is known to block protein synthesis, it was surprising 
to fi nd that cells exposed to the drugs either two or four hours after 
EBV induction, showed levels of EBV lytic antigens higher than 
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those detected in the control cells, collected at two and four hours 
after addition of IgG. A likely explanation for this result could 
rely on a decreased availability and/or activity of the two drugs 
within the 8 h period of incubation, as previously reported for CHX 
(Martin et al., 1990). Recently, an effect of RV on protein synthesis 
through the modulation of mTOR-dependent and independent 
pathways has also been reported in hepatic cells (Villa-Cuesta et 
al., 2011). Further investigations will be required to assess the 
involvement of mTOR pathways in EBV lytic cycle suppression 
by RV. Our data are apparently in contrast with those obtained by 
Yiu et al. who showed that in P3HR1 cells transfected with BRLF1 
or BZLF1 plasmids and treated with RV and sodium butyrate, the 
activity of the two promoters was inhibited by the polyphenol (Yiu 
et al., 2010). However, because sodium butyrate activates EBV 
gene expression by favoring histone acetylation and RV has been 
reported to stimulate the deacetylase activity of SIRT1 (Borra et al., 
2005), the polyphenol might annihilate the effect of sodium butyrate 
on EBV immediate early antigens promoters. In this respect, we 
consider the activation of EBV lytic cycle by IgG crosslinking in 
a cellular context that allows the coordinated expression pattern 
of EBV lytic genes, a more suitable model to study the possible 
targets/mechanisms of RV antiviral activity in vivo. 
Resveratrol has proven to exert potent antiviral activity against 
various families of DNA and RNA viruses by altering molecular 
pathways within cells affecting the viral life cycle (Campagna and 
Rivas, 2010). ROS production is considered as one of the host 
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defense reaction against microbes. We and others have reported 
an increment of ROS levels following EBV lytic cycle activation 
(Gargouri et al., 2011; Matusali et al., 2009). Moreover, it has 
been shown that oxidative stress contributes to the reactivation of 
the EBV lytic cycle through the induction of BZLF1 expression 
(Lassoued et al., 2010). Here we demonstrate that RV caused a 
strong reduction of ROS levels generated upon EBV activation. 
The anti-oxidative effect of the polyphenol was slightly reduced 
with time when concentrations lower than 40 μM were used, these 
results suggesting that increased concentration of RV can prolong 
the inhibitory effect on the burst of ROS levels generated during 
EBV lytic cycle activation. 
Following B-cell receptor cross-linking, activated signaling 
pathways lead cell-encoded transcription factors to bind to the 
promoter region of EBV immediate early gene BZLF1 and initiate 
the lytic replication process (Amon and Farrell, 2005). We report 
here that RV-mediated EBV lytic cycle inhibition involves the 
rapid suppression of NF–kB and AP-1 activation. In a similar 
cellular context, RV was found to inhibit KSHV reactivation by 
lowering the level of Egr-1, a transcription factor mediating the 
expression of RTA, the analog of BZLF1 (Dyson et al., 2012). The 
impairment in the activities of NF–kB and AP-1 might similarly 
affect both upstream, as well as downstream events of BZLF1 
expression. However, our data showing that RV does not alter 
BZLF1 transcription, suggest a prominent inhibitory effect on the 
trans-activating function of the viral product. 
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NF–kB and AP-1 are known to be redox-sensitive transcription 
factors, positively regulated by ROS levels during stress response, 
infl ammation and cellular proliferation (Angel and Karin, 1991; Lin 
and Karin, 2003). Numerous anti-oxidative and anti-infl ammatory 
phytochemicals have been used to alter abnormal cellular signaling 
mediated via NF–kB or AP-1 and prevent tumor promotion or 
progression (Ralhan et al., 2009; Shu et al., 2010). RV is demonstrated 
to modulate the expression and/or activity of transcription factors 
involved in critical pathways of carcinogenesis (Manna et al., 2000; 
Whitlock and Baek, 2012) and to inhibit COX2-induced AP-1 DNA 
binding activity in TPA-treated murine skin (Kundu et al., 2006). 
In addition, RV was found to block NF–kB activation in HCMV-
infected cells (Evers et al., 2004), HSV-1, HSV-2 (Faith et al., 2006) 
and VZV (Docherty et al., 2006). Therefore, it is conceivable that 
the RV-mediated inhibition of the EBV lytic cycle occurs, at least 
in part, through the down-regulation of critical transcription factors 
involved in the initial phases of EBV reactivation. 
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6. Conclusions
Taken together, our data indicate that in Burkitt’s lymphoma cells, 
Resveratrol is able to suppress the proliferation of latently infected 
cells and inhibit EBV productive infection upon activation of 
the lytic cycle. In particular, concerning the latent infection, we 
showed that silencing of the LMP1 viral oncogene dramatically 
increased the antitumor potential of resveratrol in latency III BL 
cells and LCLs, thus enlightening a previously unknown aspect 
of the chemotherapeutic potential of resveratrol, that is its use in 
combination with the delivery of siRNA for silencing latent EBV 
genes whose expression characterize the latency pattern of the 
tumor. 
Concerning the lytic cycle, RV treatment caused down-regulation 
of EBV lytic genes at the post-transcriptional level by affecting 
multiple cellular targets. The molecular mechanisms involved 
include: (i) inhibition of protein synthesis; (ii) a strong decrement 
of ROS levels and (iii) rapid suppression of NF–kB and AP-1 
activities, boosted by EBV lytic cycle reactivation.
Several studies are currently evaluating whether the resveratrol 
can prevent or even cure lifestyle diseases, such as cancer, diabetes 
and cardiovascular diseases. In these respects, while promising 
results have been presented at the Resveratrol 2012 International 
Conference and trials in humans are under way, clinical studies 
meant to assess the antiviral effects of the polyphenol are still 
lacking. The results obtained by this research project might provide 
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the experimental basis for further investigating in a mouse model 
the antiviral activity of this natural product against EBV infection. 
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